US Pat. No. 10,988,814

SINIPERCA CHUATSI IL-6 GENE AND DETECTION METHOD OF DISEASE-RESISTANT SNP MARKER THEREOF

SOOCHOW UNIVERSITY, Suzh...

1. A Siniperca chuatsi IL-6 cDNA comprising the cDNA sequence shown in SEQ ID NO: 1.
US Pat. No. 10,988,560

METHOD FOR PRODUCING CARBOXYL-GROUP-CONTAINING POLYMER COMPOSITION

Sumitomo Seika Chemicals ...

1. A method for producing a carboxyl group-containing polymer composition, the carboxyl group-containing polymer composition comprising:a carboxyl group-containing polymer that is a copolymer of monomers comprising an ?,?-unsaturated carboxylic acid and a compound having at least two ethylenically unsaturated groups per molecule; and
a nonionic surfactant,wherein the method comprises copolymerizing the monomers in an inert solvent in a polymerization reaction, wherein the nonionic surfactant is added into the polymerization reaction only when a polymerization degree of the ?,?-unsaturated carboxylic acid has reached 70 to 98%, and an amount of the nonionic surfactant added is 3 to 7 parts by mass per 100 parts by mass of the ?,?-unsaturated carboxylic acid.
US Pat. No. 10,987,281

SELF-ADHESIVE DENTAL COMPOSITE RESIN

KURARAY NORITAKE DENTAL I...

1. A one-part self-adhesive dental composite resin, comprising:an acid group-containing (meth)acrylic polymerizable monomer (a);
a polyfunctional (meth)acrylic polymerizable monomer (b) containing no acid group;
a photopolymerization initiator (c); and
a filler (d), wherein the filler (d) is treated with a surface treatment agent and has an average particle diameter of 0.01 to 50.0 ?m,
the surface treatment agent comprises a silane coupling agent (A) of formula (1):
CH2?C(R1)—COO—(CH2)p—Si—R2qR3(3-q)  (1),
wherein R1is a hydrogen atom or a methyl group, R2 is an optionally substituted hydrolyzable group, R3 is an optionally substituted C1 to C3 alkyl group, p is an integer of 1 to 13, and q is 2 or 3, and
an organosilazane (B) of formula (2):
R4R5R6—Si—NH—Si—R7R8R9  (2),
wherein R4, R5, and R6 are each independently a hydrogen atom or an optionally substituted C1 to C3 alkyl group, at least one of R4, R5, and R6 is an optionally substituted C1 to C3 alkyl group, R7, R8, and R9 are each independently a hydrogen atom or an optionally substituted C1 to C3 alkyl group, and at least one of R7, R8, and R9 is an optionally substituted C1 to C3 alkyl group,
wherein the total content of the filler is 50 mass % or more based on the total weight of the one-part self-adhesive dental composite resin, and
wherein the one-part self-adhesive dental composite resin does not comprise a solvent.
US Pat. No. 10,988,562

FLAME RETARDANT POLYOLEFIN-TYPE RESIN AND PREPARATION METHOD AS WELL AS OPTIC FIBER CABLE USING THE SAME

CORNING INCORPORATED, Co...

1. A method of preparing a flame retardant grafted polyolefin resin, the method comprising the steps of:reacting in an extrusion barrel a reactive polyolefin and a monomeric flame retardant agent to form the flame retardant grafted polyolefin resin, wherein the reactive polyolefin has a functional group including a moiety selected from the group consisting of anhydrides, epoxies, carboxylic acids, ketones, and isocyanates and wherein the monomeric flame retardant agent has an amine functional group and contains at least one element selected from the group consisting of phosphorus, nitrogen, silicon, and sulfur, the at least one element comprising more than 10% by weight of the monomeric flame retardant agent; and
extruding the flame retardant grafted polyolefin resin.
US Pat. No. 10,986,769

LOW DUST POWDERED SEED TREATMENT

1. A composition for minimizing fugitive dust during seed treatment comprising (a) mica coated with titanium dioxide and (b) oil powder comprising oil and maltodextrin, wherein said mica coated with titanium dioxide is about 75% by weight and said oil powder is about 25% by weight of said composition.
US Pat. No. 10,987,282

CURABLE COMPOSITION

TOKUYAMA DENTAL CORPORATI...

1. A curable composition comprising a polymerizable monomer (A); spherical particles (B) having an average primary-particle diameter in a range of 230 nm to 1,000 nm; a polymerization initiator (C), and inorganic particles (D) having an average primary-particle diameter of less than 100 nm, wherein90% or more of individual particles constituting the spherical particles (B) lies in a range of ±5% based on the average primary-particle diameter,
the polymerizable monomer (A) and the spherical particles (B) satisfy requirement (X1) represented by the following formula (1):
nP in formula (1), nP represents a refractive index at 25° C. of a polymer obtained by polymerizing the polymerizable monomer (A); and nF represents a refractive index at 25° C. of the spherical particles (B), and
when a 1 mm-thick cured product is formed from the curable composition and the Y value (Yb) of the colorimetric value according to the Munsell Color System of the colored light of the cured product on a black background and the Y value (Yw) of the colorimetric value according to the Munsell Color System of the colored light of the cured product on a white background are each measured using a color difference meter, the ratio therebetween, Yb/Yw, being within a range of 0.2 to 0.5.
US Pat. No. 10,987,283

DENTAL GLASS IONOMER CEMENT COMPOSITION FOR LUTING EXCELLENT IN REMOVABILITY

SHOFU INC., Kyoto (JP)

1. A dental glass ionomer cement composition for luting comprising at least;a component (a) acid reactive glass powder having an average particle diameter within a range of 4.5 to 7.0 ?m,
a component (b) polymer of an acid group-containing polymerizable monomer having a weight average molecular weight within a range of 30000 to 100000,
a component (c) chelating agent and
a component (d) water, wherein
a plastic flow distance of a kneaded material before setting is 2 mm or less, and
a removal possible time of an excess cement is 2 minutes or less.
US Pat. No. 10,988,821

WIRE ROD HAVING EXCELLENT COLD FORGEABILITY AND MANUFACTURING METHOD THEREFOR

POSCO, Pohang-si (KR)

1. A wire rod, comprising:carbon (C): 0.02 wt % to 0.14 wt %, silicon (Si): 0.05 wt % to 0.3 wt %, manganese (Mn): 0.5 wt % to 1.2 wt %, chrome (Cr): 0.3 wt % to 0.9 wt %, phosphorus (P): 0.02 wt % or less, sulfur (S): 0.02 wt % or less, soluble aluminum (sol. Al): 0.01 wt % to 0.05 wt %, nitrogen (N): 0.008 wt % or less, iron (Fe) as a remainder, and unavoidable impurities,
wherein, the wire rod satisfies Formula 1 and Formula 2, when the hardness of the wire rod, measured in a 1/2d position and in a 1/4d position in the diameter direction of the wire rod, are Hv, 1/2(HV) and Hv, 1/4(HV), respectively,
(Hv1/2d+Hv,1/4d)/2?150  [Formula 1]
Hv,1/2d/Hv1/4d?1.2  [Formula 2]
where d is the diameter of the wire.
US Pat. No. 10,987,285

METHOD OF RECLAIMING FORMULA COMPONENTS OF ANTIPERSPIRANT COMPOSITIONS

Colgate-Palmolive Company...

1. A method comprising:(1) melting a solid or semi-solid antiperspirant composition within a package;
(2) removing the molten antiperspirant composition from the package;
(3) settling the molten antiperspirant composition directly from steps (1) and (2) for a period of 6 to 72 hours so as to settle the molten composition into a liquid phase having an oil/wax phase, and a solid phase having an antiperspirant active;
(4) separating the solid phase from the oil/wax phase by washing the melted antiperspirant composition with water to form an aqueous phase in the liquid phase, wherein washing the melted antiperspirant composition distributes the antiperspirant active in the aqueous phase, and washing separates the solid phase from the oil/wax phase within 3 hours; and
(5) treating the liquid phase to reclaim one or more components thereof, which comprises removing the aqueous phase for reclaiming of the antiperspirant active; and saponifying the oil/wax phase.
US Pat. No. 10,988,566

DELAYED ACTION GELLING CATALYST COMPOSITIONS AND METHODS FOR MAKING POLYURETHANE POLYMERS

Evonik Operations GmbH, ...

1. A polyurethane polymer premix composition comprising at least one polyol and a catalyst composition comprising a combination of: i) at least one dimethyltin di-carboxylate salt, ii) at least one dimethyltin mercaptide salt, iii) at least one gelling tertiary amine catalyst, and iv) at least one organic carboxylic acid; wherein the at least one dimethyltin di-carboxylate salt is selected from the group consisting of dimethyltin dipropionate, dimethyltin dibutanoate, dimethyltin dipentanoate, dimethyltin dihexanoate, dimethyltin diheptanoate, dimethyltin dioctanoate, dimethyltin dinonanoate, dimethyltin didecanoate, dimethyltin diundecanoate, dimethyltin dimyristate, dimethyltin dipalmitate, dimethyltin distearate, the corresponding neo-acid derivatives including dimethyltin dineopentanoate, dimehtyltin dineohexanoate, dimethyltin dineoheptanoate, dimethyltin dineooctanoate, dimethyltin dineononanoate, dimethyltin dineoundecanoate, dimethyltin dineododecanoate, dimethyltin dineotetradecanoate, dimethyltin dineohexadecanoate, and dimethyltin dineooctadecanoate; wherein the at least one dimethyltin mercaptide salt is selected from the group consisting of dimethyltin bis(2-ethylhexylmercaptoacetate), dimethyltin bis(butylmercaptoacetate), dimethyltin bis(propylmercaptoacetate), dimethyltin bis(ethylmercaptoacetate), dimethyltin bis(methylmercaptoacetate), dimethyltin bis(pentylmercaptoacetate), dimethyltin bis(hexylmercaptoacetate), dimethyltin bis(heptylmercaptoacetate), dimethyltin bis(nonylmercaptoacetate), dimethyltin bis(decylmercaptoacetate), dimethyltin bis(undecylmercaptoacetate), dimethyltin bis(dodecylmercaptoacetate), dimethyltin bis(palmitoleylmercaptoacetate), dimethyltin bis(oleylmercaptoacetate), dimethyltin bis(linoleylmercaptoacetate), dimethyltin bis(docosahexanoylmercaptoacetate), dimethyltin bis(caprylicmercaptoacetate), dimethyltin bis(capricmercaptoacetate), dimethyltin bis(myristicmercaptoacetate), dimethyltin bis(palmiticmercaptoacetate), dimethyltin bis(stearicmercaptoacetate); wherein the at least one dimethyltin di-carboxylate salt is present in an amount between 0.01 pphp to 10 pphp, and wherein the at least one dimethyltin mercaptide salt is present in an amount between 0.01 pphp to 10 pphp.
US Pat. No. 10,988,824

CORROSION RESISTANT STEEL, METHOD FOR PRODUCING SAID STEEL AND ITS USE THEREOF

VALLOUREC OIL AND GAS FRA...

1. A steel, comprising, in weight %:0.005?C<0.03;
14?Cr?17;
2.3?Mo?3.5;
3.2?Ni?4.5;
Si?0.6;
0.5?Cu?1.5;
0.4?Mn?1.3;
0.35?V?0.6;
3.2×C?Nb?0.1;
W?1.5;
0.5?Co?1.5;
0.02?N?0.05;
Ti?0.05;
P?0.03;
S?0.005;
Al?0.05; and
iron,
wherein the steel has a microstructure comprising in area percentage between 30% and 50% of ferrite; and
wherein the steel has a yield strength of at least 758 MPa.
US Pat. No. 10,987,288

DEEP-SEA WATER CONCENTRATE SKIN APPLICATION KIT AND USE THEREOF

Yin-Ming Lo, New Taipei ...

1. A method of improving a permeability of a skincare formula, consisting of:(a) providing a skincare formula and a deep-sea water concentrate, wherein the deep-sea water concentrate comprises magnesium, sodium, potassium, and calcium minerals;
(b) mixing the skincare formula and the deep-sea water concentrate upon application to induce phase transfer of the skincare formula immediately after the mixing, so as to enhance the permeability of the skincare formula to reach to a depth of skin,
wherein a concentration of the deep-sea water concentrate is in a range from 80,000 mg/L to 420,000 mg/L, wherein a concentration of magnesium of the deep-sea water concentrate is in a range from 6,500 mg/L to 110,000 mg/L, wherein a concentration of sodium of the deep-sea water concentrate is in a range from 3,800 mg/L to 30,000 mg/L, a concentration of potassium is in a range from 400 mg/L to 18,000 mg/L, and a concentration of calcium is in a range from 100 mg/L to 500 mg/L, wherein the deep-sea water concentrate has a conductivity greater than 4.18 mS/cm, and after the deep-sea water concentrate and the skincare formula are mixed, the mixture is applied to the skin immediately.
US Pat. No. 10,987,289

AGENT FOR BLEACHING HAIR WITH AN INITIALLY RED OR RED-BLONDE HAIR COLOR

2. A method for lightening hair comprising the following steps in the specified sequence(i) producing a ready-to-use agent for lightening of keratinous fibers by mixing a first component (K1) with a second component (K2),
(ii) dispensing of the ready-to-use agent onto the keratinous fibers,
(iii) the agent remaining on the hair for a period of 1 to 60 minutes and
(iv) washing out the agent from the fibers,
wherein
the first component (K1) is cosmetic agent according to claim 1; and
the second component (K2) is an oxidizing preparation that comprises hydrogen peroxide.
US Pat. No. 10,987,291

GENTLE AGENTS AND METHODS FOR OXIDATIVE DYEING USING SELECTED DICARBOXYLIC ACIDS

1. A colouring agent for keratinous fibres, comprising—with respect to its weight—a) at least one compound selected from the group of oxidative dye precursors, direct dyes, and mixtures thereof,
b) dicarboxylic acid(s) containing from about 2 to about 10 carbon atoms, selected from malic acid, D-tartaric acid, L-tartaric acid, meso-tartaric acid, racemic acid, alpha-ketoglutaric acid, beta-ketoglutaric acid and oxaloacetic acid, and/or salt(s) of this (these) acid(s), wherein the dicarboxylic acid(s) containing from about 2 to about 10 carbon atoms are present in an amount of from about 0.1 to about 5% by weight, calculated with respect to the undissociated dicarboxylic acid and with respect to the weight of the colouring agent,
c) from about 20 to about 95% by weight of water, and
d) wherein the coloring agent is free from peroxy compounds.
US Pat. No. 10,987,037

METHOD AND APPARATUS FOR IN VIVO SURVEILLANCE OF CIRCULATING BIOLOGICAL COMPONENTS

JOHN WAYNE CANCER INSTITU...

1. A system for collecting markers associated with circulating biological components, comprising:a probe comprising a guidewire comprising a binding surface and an atraumatic distal tip, wherein the binding surface comprises an outer nanostructured polymer zone and an inner non-porous zone, wherein the nanostructured polymer zone has affixed thereto at least one binding partner for binding a marker, and wherein the nanostructured polymer zone is configured to immobilize a marker to the binding surface upon binding of the marker to the binding partner, thereby increasing the surface area of the binding surface;
wherein at least a portion of the guidewire is configured to be placed within an anatomical structure of a living organism to collect the markers.
US Pat. No. 10,987,294

STABLE SILK FIBROIN BASED PHARMACEUTICAL FORMULATIONS

EVOLVED BY NATURE, INC., ...

1. An aqueous pharmaceutical formulation comprising:a composition comprising silk fibroin-based protein fragments having about 0.01% (w/w) to about 10% (w/w) sericin, wherein the fragments have an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the fragments have a polydispersity of from about 1.5 to about 3.0,
wherein the composition is substantially homogeneous,
wherein the composition includes between 0 ppm to 500 ppm of inorganic residuals,
wherein the composition includes between 0 ppm to 500 ppm of organic residuals, and
wherein the composition does not spontaneously or gradually gelate and does not visibly change in color or turbidity when in a solution for at least 10 days.
US Pat. No. 10,988,575

FLUOROETHER COMPOSITION, COATING FLUID AND ARTICLE

AGC Inc., Chiyoda-ku (JP...

1. A fluoroether composition, comprising:a first compound and
a second compound,
wherein
a content of the first compound in the fluoroether composition, is from 20 to 85 mol %, to a total content of the first compound and the second compound,
wherein the first compound is a compound of formula (1):
[A1-O-Q1-Rf1—]a1Z1—SiR1n1L13-n1  (1)
wherein
A1 is a perfluoroalkyl group,
Q1 is a single bond, an oxyfluoroalkylene group comprising one or more hydrogen atoms, wherein an oxygen atom is bonded to Rf1, or a poly(oxyfluoroalkylene) chain comprising one or more hydrogen atoms, wherein a terminal oxygen atom is bonded to Rf1 and the oxyfluoroalkylene group bonded to Rf1 comprises one or more hydrogen atoms,
Rf1 is a poly(oxyperfluoroalkylene) chain, wherein a terminal oxygen atom is bonded to Z1,
a1 is an integer of at least 1,
wherein, when a1 is at least 2, a1 pieces of [A1-O-Q1-Rf1-] is optionally the same or different from one another,
Z1 is a (a1+1) valent connecting group,
R1 is a hydrogen atom or a monovalent hydrocarbon group,
L1 is a hydroxy group or a hydrolyzable group,
n1 is 0 or 1, and
(3?n1) pieces of L1 is optionally the same or different; and
the second compound is a compound of formula (2):
[A2-O-Q2-Rf2—]a2Z2[—SiR2n2L23-n2]b2  (2)
wherein
A2 is a perfluoroalkyl group,
Q2 is a single bond, an oxyfluoroalkylene group comprising one or more hydrogen atoms, wherein an oxygen atom is bonded to Rf2, or a poly(oxyfluoroalkylene) chain comprising one or more hydrogen atoms, wherein a terminal oxygen atom is bonded to Rf2 and the oxyfluoroalkylene group bonded to Rf2 comprises one or more hydrogen atoms,
Rf2 is a poly(oxyperfluoroalkylene) chain, wherein a terminal oxygen atom is bonded to Z2,
a2 is an integer of at least 1,
wherein, when a2 is at least 2, a2 pieces of [A2-O-Q2-Rf2-] is optionally the same or different from one another,
Z2 is a (a2+b2) valent connecting group,
R2 is a hydrogen atom or a monovalent hydrocarbon group,
L2 is a hydroxy group or a hydrolyzable group,
n2 is an integer of from 0 to 2,
wherein, when n2 is 0 or 1, (3?n2) pieces of L2 is optionally the same or different,
when n2 is 2, n2 pieces of R2 is optionally the same or different,
b2 is an integer of at least 2, and
b2 pieces of [—SiR2n2L23-n2] is optionally the same or different from one another.
US Pat. No. 10,987,296

COMPOSITION FOR IMPROVING SKIN WRINKLE CONTAINING EXOPOLYSACCHARIDE PRODUCED BY CERIPORIA LACERATA AS ACTIVE INGREDIENT

FUGENBIO CO., LTD., Seou...

1. A method of improving skin condition of a subject in need of such improvement, comprising administering a composition comprisingan extracellular polysaccharide produced by Ceriporia lacerata mycelium;
a mycelial culture medium of Ceriporia lacerata, said mycelial culture medium containing the extracellular polysaccharide;
dried powders of the mycelial culture medium containing the extracellular polysaccharide; or
an extract of the mycelial culture medium containing the extracellular polysaccharide, as an effective ingredient,
wherein the skin condition improvement is wrinkle-improvement.
US Pat. No. 10,988,833

NI—AL-RE TERNARY EUTECTIC ALLOY AND PREPARATION METHOD THEREOF

SHANGHAI JIAO TONG UNIVER...

1. A method for preparing a Ni—Al-RE ternary eutectic alloy composed of following elements by weight percent: aluminum (Al) of 2.50% to 19.50%, rare earth (RE) of 1.30% to 20.0%, other impurity elements being less than or equal to 0.10%, and the rest being nickel (Ni), comprising:preparing raw materials according to a ratio, placing the raw materials in a vacuum induction smelting furnace, vacuumizing to ensure that a vacuum degree reaches 10? Pa, increasing power to ensure complete melting of the raw materials so as to form a molten alloy melt, pouring the molten alloy melt into an iron mold, and obtaining alloy ingots that are formed of the Ni—Al-RE ternary eutectic alloy in a completely eutectic form.
US Pat. No. 10,987,298

MASCARA COMPOSITIONS COMPRISING A POLYMER HAVING CYCLIC AMIDE, CYCLIC AMINE AND ACRYLAMIDE FUNCTIONALITY

1. A mascara composition, comprising:a vehicle comprising water;
a dimethicone copolymer, present in an amount >0% and ?1% by weight;
a film-forming portion comprising
a primary film-forming polymer that is a non-ionic and water-soluble or water dispersible copolymer comprising a first cyclic amide monomer, a cyclic amine monomer, and an acrylamide monomer, the primary film-forming polymer comprising at least about 50% by weight of the film-forming portion; and
a plurality of nonionic secondary film-forming polymers; and
from about 0.5% to about 8% by weight of a C2-C5 alcohol,
wherein the plurality of at least one non-ionic secondary film-forming polymers comprises a first secondary film-forming polymer having vinyl pyrrolidone functionality and a second secondary film-forming polymer having vinylcaprolactam functionality, and
wherein at least one of the first secondary film-forming polymer or the second secondary film-forming polymer comprises a fraction of a second cyclic amide monomer that is at least about 70% by weight of the first secondary film-forming polymer or the second secondary film-forming polymer.
US Pat. No. 10,987,300

LONG LASTING COSMETIC COMPOSITIONS

Living Proof, Inc., Bost...

1. A hair treatment composition comprising a cationic polyurethane, wherein(a) the cationic polyurethane is formed from W, V, Y, Z and X, wherein
W is a polycarbonate polyol;
V is a polyisocyanate;
Y is a C1-8 alkyldiol monomer;
Z is a C1-8 aminoalkyldiol monomer; and
X is a neutralizing ion, wherein
(i) the molecular weight of W is about 1,000 g/mol;
the molar ratio of V:W is 1:0.18 to about 1:0.32;
the molar ratio of V:Y is 1:0.24 to about 1:0.72; and
the molar ratio of V:Z is 1:0.08 to about 1:0.47; or
(ii) the molecular weight of W is about 2,000 g/mol;
the molar ratio of V:W is 1:0.08 to about 1:0.18;
the molar ratio of V:Y is 1:0.36 to about 1:0.82; and
the molar ratio of V:Z is 1:0.08 to about 1:0.49; or
(iii) the molecular weight of W is about 3,000 g/mol;
the molar ratio of V:W is 1:0.05 to about 1:0.13;
the molar ratio of V:Y is 1:0.4 to about 1:0.85; and
the molar ratio of V:Z is 1:0.08 to about 1:0.49; or
(b) the cationic polyurethane is formed from W, V, Y, Z, Z1 and X, wherein
W is a polycarbonate polyol;
V is a polyisocyanate;
Y is a C1-8 alkyldiol monomer;
Z is a C1-8 aminoalkyldiol monomer;
Z1 is an ethoxylated polyol;
X is a neutralizing ion, wherein
(i) the molecular weight of W is about 1,000 g/mol;
the molar ratio of V:W is 1:0.19 to about 1:0.33;
the molar ratio of V:Y is 1:0.19 to about 1:0.7;
the molar ratio of V:Z is 1:0.08 to about 1:0.49; and
the molar ratio of V:Z1 is 1:0 to about 1:0.03; or
(ii) the molecular weight of W is about 2,000 g/mol
the molar ratio of V:W is 1:0.09 to about 1:0.18;
the molar ratio of V:Y is 1:0.31 to about 1:0.8;
the molar ratio of V:Z is 1:0.09 to about 1:0.51; and
the molar ratio of V:Z1 is 1:0 to about 1:0.03; or
(iii) the molecular weight of W is about 3,000 g/mol
the molar ratio of V:W is 1:0.05 to about 1:0.13;
the molar ratio of V:Y is 1:0.36 to about 1:0.83;
the molar ratio of V:Z is 1:0.09 to about 1:0.52; and
the molar ratio of V:Z1 is 1:0 to about 1:0.03; or
(c) the cationic polyurethane is formed from W, V, Y, Z, Z2 and X, wherein
W is a polycarbonate polyol;
V is a polyisocyanate;
Y is a C1-8 alkyldiol monomer;
Z is a C1-8 aminoalkyldiol monomer;
Z2 is a hydroxylated alkyl acid monomer;
X is a neutralizing ion, wherein
(i) the molecular weight of W is about 1,000 g/mol;
the molar ratio of V:W is 1:0.19 to about 1:0.33;
the molar ratio of V:Y is 1:0.14 to about 1:0.44;
the molar ratio of V:Z is 1:0.08 to about 1:0.47; and
the molar ratio of V:Z2 is 1:0.05 to about 1:0.33; or
(ii) the molecular weight of W is about 2,000 g/mol;
the molar ratio of V:W is 1:0.09 to about 1:0.18;
the molar ratio of V:Y is 1:0.26 to about 1:0.53;
the molar ratio of V:Z is 1:0.09 to about 1:0.49; and
the molar ratio of V:Z2 is 1:0.05 to about 1:0.35; or
(iii) the molecular weight of W is about 3,000 g/mol;
the molar ratio of V:W is 1:0.05 to about 1:0.13;
the molar ratio of V:Y is 1:0.3 to about 1:0.56;
the molar ratio of V:Z is 1:0.09 to about 1:0.5; and
the molar ratio of V:Z2 is 1:0.05 to about 1:0.35.
US Pat. No. 10,988,581

POROUS FILMS OBTAINED FROM POLYMER LATEX

Arkema France, Colombes ...

1. A porous material comprising particles of polymer P assembled by a block copolymer, the block copolymer comprising at least one block consisting of a polymer sequence immiscible with the polymer P, and at least two blocks consisting of polymer sequences miscible with the polymer P,wherein the block copolymer is a triblock copolymer of general formula ABA, in which A represents a block consisting of a polymer sequence miscible with the polymer P, and B represents a block consisting of a polymer sequence immiscible with the polymer P, andwherein Polymer P comprises a fluoropolymer.
US Pat. No. 10,988,582

SUPER ABSORBENT POLYMER AND METHOD FOR PREPARING SAME

LG Chem, Ltd.

1. A super absorbent polymer comprisinga base polymer powder including a first cross-linked polymer of a water-soluble ethylenically unsaturated monomer having at least partially neutralized acidic groups;
a surface cross-linked layer formed on the base polymer powder and including a second cross-linked polymer in which the first cross-linked polymer is further cross-linked through an alkylene carbonate having 2 to 5 carbon atoms,
hydrophobic inorganic particles that are dispersed on the base polymer powder and have a water-contact angle of 50° or more on the base polymer powder,
hydrophilic inorganic particles that are dispersed on the surface cross-linked layer and have a water-contact angle of 10° or less, and
wherein the hydrophobic inorganic particles include at least one selected from the group consisting of silica particles, titania particles and zirconia particles, and the hydrophilic inorganic particles includes at least one selected from the group consisting of silica particles, titania particles, zirconia particles, and laponite particles
wherein the super absorbent polymer has the following features:
an absorbency represented by the following Formula 1 is 45 to 65 g/g,
a saline flow conductivity for a physiological saline solution (0.685 wt % sodium chloride aqueous solution) (SFC; ?10?7 cm3?s/g) is 70 to 190 (?10?7 cm3?s/g), and
a gel strength (G?) is 9,000 to 18,000 Pa.
Absorbency=CRC+AUP  [Formula 1]
in Formula 1,
CRC represents a centrifuge retention capacity for a physiological saline solution (0.9 wt % sodium chloride aqueous solution) of the super absorbent polymer for 30 minutes,
AUP represents an absorbency under pressure under 0.7 psi for a physiological saline solution (0.9 wt % sodium chloride aqueous solution) of the super absorbent polymer for 1 hour, and
the gel strength (G?) represents a horizontal gel strength of the super absorbent polymer measured using a rheometer, after absorbing and swelling a physiological saline solution (0.9 wt % sodium chloride aqueous solution) to the super absorbent polymer for 1 hour.
US Pat. No. 10,987,303

EXTENDED RELEASE SUSPENSION FORMULATION OF LURASIDONE

LifeMax Laboratories, Inc...

1. A depot formulation of lurasidone comprising crystals of lurasidone or an acid salt thereof and having a mean particle size of about 4 ?m to about 100 ?m,wherein the concentration of lurasidone crystals in the formulation is greater than about 250 mg/mL;
wherein the formulation comprises a suspending agent comprising PEG 4000 in an amount of about 5% (w/w);
wherein the formulation comprises a surfactant comprising polysorbate 20 in an amount of from about 1% (w/w) to about 2% (w/w);
wherein the depot formulation is suitable for injection via a syringe needle having a gauge size of 22 gauge or smaller; and
wherein, upon administration, the formulation delivers a therapeutic dose of lurasidone for at least about 28 days.
US Pat. No. 10,988,584

RESIN FOR FOAM MOLDING, FOAM MOLDED ARTICLE, AND METHOD FOR PRODUCING SAME

KYORAKU CO., LTD., Kyoto...

1. A resin for foam molding, comprising a component A, a component B and a component C, whereinthe component A is a long-chain branched homopolypropylene,
the component B is a long-chain branched block polypropylene,
the component C is a polyethylene-based elastomer, and
when a total of the components A to C is 100 parts by mass, content of the component A is 20 to 70 parts by mass, content of the component B is 20 to 70 parts by mass, and content of the component C is 1 to 20 parts by mass.
US Pat. No. 10,987,304

OCULAR DELIVERY OF DRUGS

Nanomerics Ltd., St. Alb...

1. A topical ocular formulation comprising an aqueous composition comprising a macrolide immunosuppressant drug selected from sirolimus, cyclosporine A, tacrolimus, and everolimus at a concentration of less than 2% w/v and quaternary ammonium palmitoyl glycol chitosan (GCPQ) at a concentration below 10% w/v, wherein the ratio of the concentration in w/v of GCPQ to the drug is greater than 5:1, and wherein GCPQ has a palmitoylation level between 10 mole % and 40 mole % and a quaternization level between 6 mole % and 20 mole %, wherein the formulation has a pH from 6.5 to 7.4.
US Pat. No. 10,987,306

METHODS OF TREATMENT OF VAGINOSIS AND VULVOVAGINITIS

Eve Pharma Ltd., Or-Yehu...

1. A method of treatment of vaginosis or vulvovaginitis comprising:administering to a subject in need thereof a vaginal solid composition comprising a therapeutically effective amount of at least one active agent, a pH-dependent polymer, and optionally a pH indicator, wherein the pH-dependent polymer dissolves at a pH greater than 4.5, wherein the subject in need thereof has a vaginal pH greater than 4.5, wherein the vaginal pH greater than 4.5 is indicative of vaginosis and vulvovaginitis,
wherein the solid composition is a capsule, an insert, a matrix or suppository,
retrieving the composition,
discontinuing treatment of vaginosis or vulvovaginitis if the solid composition is not disintegrated, if the optional pH indicator indicates a pH of 4.5 or below, or combination thereof.
US Pat. No. 10,988,587

POLYMER COMPOSITION FOR HIGHLY DISINTEGRATABLE FILM

NOVAMONT S.P.A., Novara ...

1. A film comprising a composition comprising:i) 55-80% by weight, with respect to the total weight of the composition, of at least one aliphatic polyester (i) comprising:
a) a dicarboxylic component comprising with respect to the total dicarboxylic component:
a1) 70-100% by moles of units deriving from succinic acid, and
a2) 0-30% by moles of units deriving from at least one saturated dicarboxylic acid different from succinic acid, and
b) a diol component comprising with respect to the total diol component:
b1) 95-100% by moles of units deriving from 1,4-butanediol, and
b2) 0-5% by moles of units deriving from at least one saturated aliphatic diol different from 1,4-butanediol;
ii) 5-40% by weight, with respect to the total weight of the composition, of at least one aliphatic-aromatic polyester (ii) comprising:
a) a dicarboxylic component comprising with respect to the total dicarboxylic component:
a1) 30-70% by moles of units deriving from at least one aromatic dicarboxylic acid, and
a2) 70-30% by moles of units deriving from at least one saturated aliphatic dicarboxylic acid,
b) a diol component comprising with respect to the total diol component:
b1) 95-100% by moles of units deriving from at least one saturated aliphatic diol, and
b2) 0-5% by moles of units deriving from at least one unsaturated aliphatic diol; and
iii) 1-25% by weight, with respect to the total weight of the composition, of at least one polyhydroxyalkanoate,
said film having an impact strength index of at least 2 mJ/(g/m2), measured according to standard ASTM D3420-08a.
US Pat. No. 10,986,794

MAIZE HYBRID X08N735

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X08N735, representative seed produced by crossing a first plant of variety PH41F0 with a second plant of variety PH47CK, wherein representative seed of the varieties PH41F0 and PH47CK have been deposited under ATCC Accession Numbers PTA-124792 and PTA-126662, respectively.
US Pat. No. 10,988,588

CURABLE RESIN FOR MINERAL WOOL

URSA Insulation, S.A., M...

1. A curable resin for the manufacture of mineral wool, comprising components a), b) and c), wherein:a) is a saccharide;
b) is a polycarboxylic crosslinking agent; and
c) is a polyvalent metal oxide selected from the group of metal oxides consisting of group 2 or 12 of the International Union of Pure and Applied Chemistry periodic table; wherein zinc oxide is absent from the curable resin.
US Pat. No. 10,988,844

PROCESS FOR PRODUCING FLEXIBLE ORGANIC-INORGANIC LAMINATES

BASF Coatings GmbH, Muen...

1. A process for producing a laminate, the process comprising a sequence comprising:(a) depositing an inorganic layer by an atomic layer deposition process; and
(b) depositing an organic layer comprising an aromatic selenol comprising one or more hydroxyl groups by a molecular layer deposition process, wherein the selenol is directly bound to the aromatic group;
wherein the sequence is performed more than once,
wherein the inorganic layer is deposited by 4 to 150 atomic layer deposition cycles, and
wherein each organic layer is deposited by one molecular layer deposition cycle.
US Pat. No. 10,986,795

SOYBEAN VARIETY 5PRWC37

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PRWC37, representative seed of the variety having been deposited under ATCC Accession Number PTA-126094.
US Pat. No. 10,987,308

THERAPEUTIC NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS

GENESEGUES, INC., Chaska...

1. A pharmaceutical composition comprising nanoparticles, wherein the nanoparticles comprise: at least one bioactive agent, a surfactant having an hydrophile-lipophile balance (HLB) value of less than 6.0 units, a ligand, and Li+ and Cs+, wherein:i) the at least one bioactive agent and the surfactant form a surfactant micelle core;
ii) the ligand forms a shell which substantially coats the nanoparticles; and
iii) the nanoparticles have an average diameter of less than about 50 nanometers, and the nanoparticles have increased stability resulting from treatment with Li+ pretreated with Cs+, as compared to nanoparticles treated with (i) Li+ and without Cs+ or (ii) Li+ and Cs+ mixtures but not Li+ pretreated with Cs+ mixtures.
US Pat. No. 10,988,589

THERMOSETTING RESIN COMPOSITION, PREPREG, AND FIBER-REINFORCED COMPOSITE MATERIAL AND PRODUCTION METHOD THEREFOR

Mitsubishi Chemical Corpo...

1. A thermosetting resin composition comprising:an epoxy resin;
an epoxy resin curing agent;
an imidazole compound; and
an epoxy resin curing accelerator,
wherein the epoxy resin curing agent comprises dicyandiamide or a derivative thereof,
wherein the imidazole compound comprises an isocyanuric acid addition product of imidazole or an isocyanuric acid addition product of an imidazole derivative, and
wherein the epoxy resin curing accelerator comprises a urea derivative having two or more dimethylureido groups in a molecule.
US Pat. No. 10,986,796

MAIZE HYBRID X15N058

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X15N055, representative seed produced by crossing a first plant of variety PH2RDY with a second plant of variety PH40WC, wherein representative seed of the varieties PH2RDY and PH40WC have been deposited under ATCC Accession Numbers PTA-124579 and PTA-124819, respectively.
US Pat. No. 10,987,309

TABLET CAPABLE OF COMBATTING MISUSE BY INJECTION

ETHYPHARM, Saint-Cloud (...

1. An oral pharmaceutical composition in the form of a sustained-release matrix tablet, the matrix consisting of:from 10% to 40% by weight relative to the total weight of the composition of at least one active ingredient likely to be misused for drug addiction purposes; and
a combination of:
from 20% to 60% by weight relative to the total weight of the composition of a mixture of polyvinyl acetate and polyvinylpyrrolidone,
from 15% to 25% by weight relative to the total weight of the composition of xanthan gum,
from 10% to 30% by weight relative to the total weight of the composition of a carbomer,
from 1% to 20% by weight relative to the total weight of the composition of a pH stabilizing agent, and
at least one anti-adherent agent,
wherein the carbomer is a polymer of acrylic acid of high molecular weight cross-linked with allyl sucrose or allyl ethers of pentaerythritol;
wherein the pH stabilizing agent comprises at least one compound chosen from: citric acid and sodium bicarbonate;
wherein said combination prevents misuse by injection by forming a gel trapping the active ingredient and having a viscosity such that the gel cannot pass through a needle when the composition is reduced to powder and dissolved in an injectable volume of an aqueous or hydro-alcoholic solution, and such that the amount of active ingredient extracted in an aqueous medium is lower than 25%; and
wherein the active principle is released over a period of more than 20 hours, and wherein said tablet has a yield strength higher than 6 MPa.
US Pat. No. 10,988,590

HIGHLY TRANSPARENT COATED CELLULOSE TRIACETATE FILM AND DISSOLVER MEDIUM

Island Polymer Industries...

1. A highly transparent coated film based on cellulose triacetate consisting of a support film and a coating layer,a) the support film comprising:
a1) a cellulose triacetate with a haze value of <0.5% and further defined by:
a content of gel-forming components of ?0.5%,
cotton linters as raw material base,
a water content of <1%,
a proportion of free acetic add of ?300 ppm,
a very slight yellow coloration, characterized by a low Hazen color number (APHA value) <70 determined on a 16% solution of cellulose triacetate, dissolved in methylene chloride according to the ASTM D-1209 method and,
a proportion of <0.5% of foreign fibers and particles having a size of ?5.40 ?m,
a2) at least one organic or inorganic substance, which is effective as bonding agent and spacer between the molecular chains of the cellulose triacetate and acts as a plasticizer to promote flexibility and elasticity of the support film,
a3) a surface layer disposed on one side or both sides of the support film and based on a cellulose ester mixture or a cellulose ester mixture that is fully dissolved or initially dissolved in halogen alkanes, ketones, ethers, esters, deep eutectic solvents or alcohols and/or an acrylate mixture which is crosslinkable with UV light, chemically or by supplying thermal energy,
a4) functional additives from the following groups in a proportion between 0.001 mass % and 15 mass %:
organic or inorganic substances with a transmission-influencing absorptive function in the wavelength range of 300 nm to 2,500 nm, microscale or nanoscale additives for adhesion, slip or electrostatic properties,
crosslinking agents,
stabilizers and/or antioxidants,
b) the coating layer applied by a coating solution comprising,
b1) at least two solvents selected from the group consisting of ethers, esters, ketones, aromatics and deep eutectic solvents (DES)
b2) at least one acrylate copolymer with an average molecular weight MW between 100,000 and 150,000 g/mole, a glass transition temperature of at least 35° C. and a solubility or swellability in at least one solvent,
b3) at least one cellulose derivative with a solubility of at least 10 g/liter in a solvent selected from the group consisting of ketones, ethers, deep eutectic solvents and alcohols, and
b4) one or more plasticizers in an amount between 0.01% by mass and 15% by mass.
US Pat. No. 10,986,797

SOYBEAN CULTIVAR 86440139

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar 86440139, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 201911015.
US Pat. No. 10,987,310

CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES

JAZZ PHARMACEUTICALS, INC...

1. A formulation comprising immediate release and sustained release portions, each portion comprising at least one pharmaceutically active ingredient selected from gamma-hydroxybutyrate and pharmaceutically acceptable salts of gamma-hydroxybutyrate, wherein:a. the sustained release portion comprises a functional coating and a core, wherein the functional coating is deposited over the core, wherein the core comprises at least one pharmaceutically active ingredient selected from gamma-hydroxybutyrate and pharmaceutically acceptable salts of gamma-hydroxybutyrate; wherein the functional coating comprises one or more methacrylic acid-methyl methacrylate co-polymers that are from about 20% to about 50% by weight of the functional coating; the sustained release portion comprises about 500 mg to 12 g of at least one pharmaceutically active ingredient selected from gamma-hydroxybutyrate and pharmaceutically acceptable salts of gamma-hydroxybutyrate; and the sustained release portion releases greater than about 40% of its gamma-hydroxybutyrate by about 4 to about 6 hours when tested in a dissolution apparatus 2 in deionized water at a temperature of 37° C. and a paddle speed of 50 rpm;
b. the immediate release portion further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of copovidone, plasacryl, hydroxypropyl cellulose, hydroxypropyl methylcellulose and hydroxymethyl cellulose, and the amount of gamma-hydroxybutyrate and pharmaceutically acceptable salts of gamma-hydroxybutyrate in the immediate release portion is about 10% to 50% by weight of the gamma-hydroxybutyrate and pharmaceutically acceptable salts of gamma-hydroxybutyrate in the formulation;
c. the formulation releases at least about 30% of its gamma-hydroxybutyrate by one hour when tested in a dissolution apparatus 2 in deionized water at a temperature of 37° C. and a paddle speed of 50 rpm; and
d. the formulation releases greater than about 90% of its gamma-hydroxybutyrate by 8 hours when tested in a dissolution apparatus 2 in deionized water at a temperature of 37° C. and a paddle speed of 50 rpm.
US Pat. No. 10,987,822

METHOD FOR ESTABLISHING A POSTERIORI A MATCH BETWEEN A PIECE OF WOOD AND A LOG FROM WHICH THE PIECE OF WOOD HAS BEEN OBTAINED

MICROTEC S.R.L., Bressan...

1. A method for establishing a posteriori a match between a piece of wood and a log from which the piece of wood has been obtained, comprising the following operating steps:an initial step of taking a wooden log;
a scanning step, wherein a tomographic scan of the wooden log is performed;
a step of choosing a cutting pattern, during which a cutting pattern for the log is calculated or selected, the cutting pattern comprising information with reference to a subsequent division of the log into pieces of wood;
a characterising step, during which for each virtual piece of wood intended to be obtained with the cutting pattern, and starting with the tomographic information available, one or more virtual individualising characteristics are defined which are linked to the distribution and/or size of physical characteristics of the log inside and/or on the surface of the self-same virtual piece of wood;
a saving step, during which those virtual individualising characteristics of each virtual piece of wood are saved in a database, together with information about the identity of the log;
a cutting step, during which the log is divided into real pieces of wood according to what is foreseen in the cutting pattern;
a selecting step, during which a real piece of wood obtained from the cutting step is selected;
an analysing step, during which real information about the distribution and/or size of physical characteristics of the log inside and/or on the surface of the real piece of wood is acquired and, based on that real information, corresponding real individualising characteristics of the real piece of wood are defined;
a search step, during which the real individualising characteristics of the real piece of wood are compared with the virtual individualising characteristics saved in the database for virtual pieces of wood, in order to identify a match;
and an identifying step, during which an origin of the real piece of wood is identified based on the information about the identity of the log which is saved in the database together with the virtual individualising characteristics of a virtual piece of wood which match the real individualising characteristics of the real piece of wood.
US Pat. No. 10,986,798

SOYBEAN CULTIVAR 82230919

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar 82230919, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 201911016.
US Pat. No. 10,986,799

SOYBEAN CULTIVAR 81440919

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar 81440919, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 201911017.
US Pat. No. 10,986,800

SOYBEAN VARIETY 5PKNB14

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PKNB14, representative seed of the variety having been deposited under ATCC Accession Number PTA-126234.
US Pat. No. 10,986,801

SOYBEAN VARIETY 5PLTM45

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PLTM45, representative seed of the variety having been deposited under ATCC Accession Number PTA-126235.
US Pat. No. 10,987,314

ANTIGEN-SPECIFIC, TOLERANCE-INDUCING MICROPARTICLES AND USES THEREOF

University of Florida Res...

1. A method for reducing an immune response to an antigen in a subject, wherein the method comprises administering, to a subject in need of such tolerance:a dual microparticle system for targeting an antigen-presenting immune cell of interest in the subject and for reducing an immune response to an antigen, wherein the microparticle system is a liquid formulation that comprises:
microparticles that are phagocytosable by the antigen presenting immune cell of interest, and microparticles that are non-phagocytosable by the antigen-presenting immune cell of interest, wherein the phagocytosable microparticles together comprise an antigen and at least one immunomodulatory agent selected from vitamin D3, vitamin D3 analog, glucocorticoid, estrogen, rapamycin, and retinoic acid; wherein the non-phagocytosable microparticles together comprise at least one immunosuppressive tolerogenic agent selected from IL-10, TGF-?, and nonsteroidal anti-inflammatory drugs (NSAIDs), and an agent that recruits the antigen-presenting immune cell of interest selected from GM-CSF, G-CFS, and M-CSF; wherein the phagocytosable microparticle and the non-phagocytosable microparticles are made of PLGA.
US Pat. No. 10,986,802

SOYBEAN VARIETY 5PELW66

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PELW66, representative seed of the variety having been deposited under ATCC Accession Number PTA-126249.
US Pat. No. 10,987,315

ANTITHROMBOTIC NANOPARTICLES AND METHODS FOR TREATING NECROTIZING ENTEROCOLITIS

University of South Flori...

1. A method of treating necrotizing enterocolitis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antithrombotic nanoparticle comprising a thrombin inhibitor.
US Pat. No. 10,986,803

SOYBEAN CULTIVAR 2040178

Benson Hill Seeds, Inc., ...

1. A plant or a seed of soybean cultivar 2040178, wherein a representative sample of seed of said cultivar is deposited under NCMA No. 202011003.
US Pat. No. 10,987,316

COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF TERTIARY AMINE DRUGS

NOVEN PHARMACEUTICALS, IN...

1. A transdermal drug delivery system comprising:a polymer matrix formed by blending the free base form of a tertiary amine drug and at least one carboxyl group-containing compound, wherein the relative amounts of free base and carboxyl group-containing compound is such that greater than 50% of the free base is associated with a carboxylic acid group to form a salt, and
a backing layer,
wherein the transdermal drug delivery system releases drug upon application to skin, and is effective to deliver a therapeutically effective amount of the tertiary amine drug through skin for at least 3 days.
US Pat. No. 10,986,804

SOYBEAN CULTIVAR 2529309

Benson Hill Seeds, Inc., ...

1. A plant or a seed of soybean cultivar 2529309, wherein a representative sample of seed of said cultivar is deposited under NCMA No. 202011005.
US Pat. No. 10,988,598

HIGH REFRACTIVE INDEX SOLVENT FREE SILICONE NANOCOMPOSITES

PIXELLIGENT TECHNOLOGIES,...

1. A solvent-free dispersion comprising:a silicone matrix, and
nanocrystals at least partially capped with at least one capping agent in the silicone matrix, wherein
the at least one capping agent comprises a silicone capping agent, and wherein
a sample of the dispersion containing 50-60 wt. % of the at least partially capped nanocrystals has a normal transmittance (Tn) of 50% to 90% when measured in a 1 cm cuvette at wavelengths of 450 nm, 500 nm, 550 nm or 600 nm, wherein
the at least partially capped nanocrystals are optionally at least partially capped with at least one silicone capping agent comprising a head group and a tail group wherein the head group anchors the at least one capping agent to a surface of the nanocrystals through a covalent bond through an M-O-M? linkage, where one of M and M? is a metal and the other of M and M? is silicon.
US Pat. No. 10,988,854

FLEXIBLE COLOR ADJUSTMENT FOR DARK CR(III) PLATINGS

MacDermid Enthone Inc., ...

2. A method for adjusting a color of an electrolytically deposited chromium finish on a workpiece, the method comprising the steps of:a) providing an electroplating bath comprising chromium(III)-ions and sulfur containing organic compounds,
b) filtering the electroplating bath to remove at least a portion of the concentration of the sulfur containing organic compounds in the bath by passing the electroplating bath through an activated carbon filter; and
c) placing the workpiece into the electroplating bath to electrodeposit a chromium finish on the workpiece;
wherein the activated carbon filter is configured to preferentially remove sulfur containing organic compounds from the bath, such that adsorption of sulfur containing organic compounds by the activated carbon filter is at least two times higher than adsorption of other bath components; and
wherein the removal of the sulfur containing organic compounds from the bath adjusts a lightness L* of the electrolytically deposited chromium finish on the workpiece.
US Pat. No. 10,986,805

SOYBEAN VARIETY 5PQYD12

DOW AGROSCIENCES LLC, In...

1. A plant or a seed of soybean variety 5PQYD12, representative seed of the variety having been deposited under ATCC Accession Number PTA-126165.
US Pat. No. 10,988,599

METHOD OF PRODUCING PLANT BIOMASS-BASED BIOPLASTIC

1. A method for producing a pumpkin based bioplastic, the method comprising: providing a pumpkin, the pumpkin comprising pumpkin flesh and pumpkin seeds; providing reinforcing fibers selected from the group consisting of pumpkin stem derived fibers and corn stalk pith fibers; separating the pumpkin flesh from the pumpkin seeds; extracting oil from the pumpkin seeds; separating organic glycerin from the oil; combining the organic glycerin, the pumpkin flesh and the reinforcing fibers to produce a pumpkin based bioplastic.
US Pat. No. 10,990,647

FLEXIBLE VECTOR-PROCESSING ALGORITHMS FOR NUMERICALLY SOLVING EXTREME-SCALE, LINEAR AND NON-LINEAR, PREDICTIVE AND PRESCRIPTIVE, PROBLEMS IN SCIENCE AND ENGINEERING, ON PARALLEL-PROCESSING SUPER COMPUTERS

1. A computer-implemented method generating a numerical solution of a convex programming problem, comprising the computer-implemented steps of:reformulating the convex programming problem as an equivalent generalized convex programming optimization problem with only linear constraints, and solving the equivalent generalized convex programming optimization problem by vector processing, comprising determining by computer-implemented numerical computation a solution for an unconstrained objective function whose independent vector variable is the generalized convex programming conjugate dual of a primal decision vector variable of the convex programming problem, and comprises a variable linear combination of fixed vectors enabling the vector processing, thereby reducing computational complexity and speeding the computer's numerical computation of the solution;
wherein the convex programming problem is selected from the group consisting of: multi-scale climate modeling; modeling of controlled nuclear fusion; modeling of physiological processes; modeling of nanoscale electronic devices and microelectromechanical systems (MEMS);
pharmaceutical drug design; design of materials selected from the group consisting of high temperature superconductors, quantum computing components, and structural nanomaterials; modeling of planetary, interstellar, and galactic systems; design of particle accelerators; modeling of population dynamics; design of pandemic intervention models; optimization of global supply chains; design of multinational disaster response systems; modeling of seismological activity and events; design and optimization of robotic systems; optimization of resource allocation in resource-constrained environments; political forecasting; modeling of combustion energy systems; modeling of dark energy and dark matter interactions and environments; modeling of exaJoule-level energy flows; design and optimization of exaFLOP computing systems; modeling of nanoscale sensor monitoring systems; and Markowitz portfolio selection; and
wherein the method comprises outputting a solution on a graphical user interface or other output component of the computer.
US Pat. No. 10,988,600

CYCLODEXTRIN-GRAFTED CROSS-LINKED HYALURONIC ACID COMPLEXED WITH ACTIVE DRUG SUBSTANCES AND USES THEREOF

GALDERMA HOLDING SA, La ...

1. A hyaluronic acid product comprising:(a) a cross-linked hyaluronic acid and one or more aminocyclodextrin host molecules, wherein the hyaluronic acid is cross-linked by ether bonds and wherein the one or more aminocyclodextrin host molecules are grafted onto the cross-linked hyaluronic acid by direct amide bonds between an amino group of the one or more aminocyclodextrin host molecules and a carboxyl group of the cross-linked hyaluronic acid; and
(b) one or more guest molecules comprising 4-(2-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)sulfonyl)ethyl)benzoic acid;
wherein the one or more guest molecules form a guest-host complex with the one or more aminocyclodextrin host molecules.
US Pat. No. 10,988,601

CARBOXYLIC ACID-MODIFIED NITRILE-BASED COPOLYMER LATEX AND LATEX COMPOSITION FOR DIP MOLDING COMPRISING SAME

LG Chem, Ltd.

1. A carboxylic acid-modified nitrile-based copolymer latex prepared by copolymerizing components comprising monomers including a conjugated diene-based monomer, an ethylenically unsaturated nitrile-based monomer, an unsaturated carboxylic acid monomer, an unsaturated dicarboxylic acid monomer; and a sulfur oxyanion compound,wherein 80 wt. % or more of a total content of the unsaturated carboxylic acid monomer, the unsaturated dicarboxylic acid monomer and the sulfur oxyanion compound is present in a copolymerized state on a surface of a carboxylic acid-modified nitrile-based copolymer latex particles, and
wherein in the copolymerizing, the sulfur oxyanion compound is contained in an amount of 0.1 to 2 parts by weight is used relative to 100 parts of the monomers, wherein the conjugated diene-based monomer is contained in an amount of 35 wt. % to 80 wt. % of is used based on a total content of the monomers, the ethylenically unsaturated nitrile-based monomer is contained in an amount of 20 wt. % to 50 wt. % of based on a total content of the monomers, the unsaturated carboxylic acid monomer is contained in an amount of 2 wt. % to 10 wt. % based on a total content of the monomers, and the unsaturated dicarboxylic acid monomer is contained in an amount of 0.1 wt. % to 3 wt. % based on a total content of the monomers.
US Pat. No. 10,987,321

CANNABINOID AND ANESTHETIC COMPOSITIONS AND METHODS

1. An oral therapeutic composition, comprising:carboxymethyl cellulose in an amount of from about 1 wt % to about 25 wt %;
a biocompatible polymer in an amount of from about 1 wt % to about 10 wt %;
a polyalcohol in an amount of from about 1 wt % to about 70 wt %;
a cross-linking agent in its salt form and in an amount of from about 0.1 wt % to about 5 wt %;
at least one cannabinoid is in an amount of from about 1 wt % to about 20 wt %; and
an effective amount of at least one anesthetic,
wherein the composition has less than 0.5% water and the cross-linking agent remains in its salt form until the oral therapeutic composition is placed in an oral cavity.
US Pat. No. 10,988,603

MOLDED RESIN STRAND

KYORAKU CO., LTD., Kyoto...

1. A molded resin strand comprising:60 to 79 mass % of thermoplastic resin;
20 to 30 mass % of an inorganic filler; and
1 to 10 mass % of ?-olefin elastomer, wherein
the thermoplastic resin is polypropylene, and
the molded resin strand is a molded resin strand used for a 3D printer employing a fused deposition modeling method.
US Pat. No. 10,988,605

PVC COMPOSITIONS, FILMS, LAMINATES AND RELATED METHODS

Avery Dennison Corporatio...

1. A vinyl film comprising:polyvinyl chloride (PVC);
at least one plasticizer;
at least one UV stabilizer;
at least one heat stabilizer; and
at least one print additive;
wherein the PVC includes:
from 15 to 60 parts per hundred of a low molecular weight PVC resin;
from 15 to 60 parts per hundred of an intermediate molecular weight PVC resin; and
from 40 to 90 parts per hundred of a high molecular weight PVC resin; and
wherein the film has a thickness within a range of from 1.20 mils (30.5 microns) to 2.00 mils (50.8 microns).
US Pat. No. 10,987,326

BUTYRATE AND BETA-HYDROXYBUTYRATE COMPOSITIONS

1. A composition comprising:(a) purified butyrate or esters or propionate salts thereof, wherein the purified butyrate includes a butyrate sodium salt, a butyrate calcium salt, or a butyrate magnesium salt; and
(b) purified beta-hydroxybutyrate or esters or propionate salts thereof, wherein the purified beta-hydroxybutyrate includes a beta-hydroxybutyrate sodium salt, a beta-hydroxybutyrate calcium salt, or a beta-hydroxybutyrate magnesium salt, wherein the composition is packaged in a form selected from the group consisting of (i) an oral capsule, (ii) in powdered form, (iii) in an aqueous or non-aqueous liquid, (iv) in an oil-in-water or water-in-oil emulsion, (v) in an elixir or syrup, or (vi) in a paste, wherein the composition is effective to deliver 1000- 5000 mg of a short chain fatty acid and 1000-10,000 mg of ketone to a person on a daily basis.
US Pat. No. 10,987,331

METHODS OF TREATING MIXED DYSLIPIDEMIA

Amarin Pharmaceuticals Ir...

1. A method of treating or preventing stroke and/or myocardial infarction in a subject on statin and anticoagulant/antiplatelet therapy and having elevated triglycerides of at least about 150 mg/dL, the method comprising coadministering to said subject about 4 g of ethyl icosapentate per day with the subject's statin and anticoagulant/antiplatelet therapy, wherein the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.
US Pat. No. 10,987,846

THIN FILM COMPOSITE HOLLOW FIBER MEMBRANES FOR OSMOTIC POWER GENERATION

National University of Si...

1. A method of generating osmotic power comprising:providing a thin film composite (TFC) hollow fiber including an outer support layer and an inner thin film layer,
wherein the outer support layer is formed of polyethersulfone and has a thickness of 10 to 10,000 ?m, a sponge-like structure, an overall porosity of about 75%, a mean pore diameter within the range of about 8 nm to about 12 nm, and a geometric standard deviation of about 1.2,
the inner thin film layer is adherent to the outer support layer, is formed of cross-linked polyamide, and has a thickness of 1 to 10,000 nm, and
the hollow fiber has a transmembrane pressure resistance rate of about 20 bar or higher, a pure water permeability rate of about 3.3 Lm?2h?1bar?1 or higher, and a salt permeability rate of about 0.4 Lm?2h?1bar?1 or lower; and
subjecting the TFC hollow fiber to a pressure-retarded osmosis process by contacting the inner thin film layer with a pressurized draw solution and contacting the outer support layer with a feed solution so as to provide a power density rate of about 8 Wm?2 or higher.
US Pat. No. 10,991,948

SURFACE-TREATED COPPER FOIL FOR LITHIUM-ION SECONDARY BATTERIES

CHANG CHUN PETROCHEMICAL ...

1. A surface-treated copper foil comprising;a copper foil having a first side and an opposite-facing second side,
two treatment layers, one of the treatment layers is disposed on the first side, and the other one of the treatment layers is disposed on the opposite-facing second side, and each treatment layer, respectively, providing a treated surface on the copper foil,
wherein each of the treated surfaces on the copper foil exhibits a ten-point average roughness Rz in a range of 1.52 ?m to 4.51 ?m and a peak density (Spd) in a range of 498,526 to 1,079,838 mm?2, and
wherein the Cr content in each of the two treatment layers is in a range of 30.2 to 69.7 ?g/dm2.
US Pat. No. 10,988,622

TEMPORARY PROTECTIVE COATING AND REMOVAL SYSTEM

TSYTEX E-COATINGS INC.

1. A coating composition for providing a temporary protective coating onto a glass surface of a building construction element, the coating composition having a VOC content of ?30 grams/litre and comprising an alkali-soluble resin comprising an acrylic polymer or copolymer, the temporary protective coating being fully soluble in and completely removable from the glass surface without leaving residues using an aqueous alkali solution, wherein the coating composition is free of heavy metals and ammonia.
US Pat. No. 10,988,623

GLOSS REMOVABLE COATING

The Sherwin-Williams Comp...

1. A coating composition comprising: at least one hydrocarbon solvent, at least one resin, and at least one filler, wherein the filler is silica-deficient and wherein the resin comprises styrene-ethylene-butylene styrene copolymer and styrene, and wherein the composition, when applied to a substrate and allowed to dry, produces a coating which can be removed from the substrate by physical means only.
US Pat. No. 10,991,952

CATALYST

3M Innovative Properties ...

1. A catalyst comprising nanostructured element comprising microstructured whiskers having an outer surface at least partially covered by a catalyst material having the formula PtxNiyAuz, wherein x is in a range from 27.3 to 29.9, y is in a range from 63.0 to 70.0, and z is in a range from 0.1 to 9.6.
US Pat. No. 10,987,346

ILOPERIDONE FOR THE TREATMENT OF SCHIZOPHRENIA

Vanda Pharmaceuticals Inc...

1. In a method consisting essentially of treating a schizophrenia patient by administering therapeutic amounts of a compound that is iloperidone or P88 or a pharmaceutically-acceptable salt of iloperidone or P88 daily, the improvement comprising:after completion of an acute treatment phase in which the schizophrenia patient is administered the compound at a first dose of 12-24 mg/day, reducing the amount of the compound administered daily to a second dose that is both smaller than the first dose and in a range of 8-16 mg/day.
US Pat. No. 10,988,371

METHODS OF MANUFACTURING MEDICAL PADS

1. A method for manufacturing a medical pad from a compromised medical pad, wherein the compromised medical pad comprises a fill material and an external cover surrounding the fill material, the method comprising: extracting the fill material from the external cover of the compromised medical pad; and exposing the extracted fill material to UV-C output from a UV-C source for a time and under conditions sufficient to achieve at least a 3 log reduction in surface level microorganism activity to produce decontaminated fill material; and covering the decontaminated fill material with a new external cover.
US Pat. No. 10,986,834

PEPTIDE-CONTAINING COMPOSITION AND STABILIZER, STABILIZING METHOD, AND STORAGE METHOD FOR PEPTIDE

KANEKA CORPORATION, Osak...

1. A method for cultivating a plant, comprising applying a peptide-containing composition to a cultivation carrier comprising soil in which a body of the plant has been fixed,wherein the composition comprises a peptide, an alkaline mineral carrier, clay, and one or more selected from the group consisting of a surfactant, carboxymethylcellulose, a salt of carboxymethylcellulose, polyvinyl alcohol, and potassium,
wherein an amount of the alkaline mineral carrier is 8 parts by mass or more based on 100 parts by mass of the peptide,
wherein the peptide is oxidized-glutathione, and
wherein the alkaline mineral carrier is one or more selected from the group consisting of talc and mica.
US Pat. No. 10,987,347

PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME

GENUS LIFESCIENCES INC., ...

1. A method for induction of local anesthesia prior to performing a medical procedure on, through, or adjacent to a mucous membrane of a nasal cavity of a patient comprising:determining a Child-Pugh score for a patient;
soaking a plurality of absorbent articles in an aqueous solution comprising, by weight, about 3.6% to about 4.4% cocaine hydrochloride, about 0.07% to about 0.20% sodium benzoate, and citric acid; and
contacting at least one of the plurality of absorbent articles with a mucous membrane of the patient for up to about 20 minutes to reduce sensation in a body region of the patient, if the patient has a Grade A Child-Pugh score.
US Pat. No. 10,986,835

USE OF 9-TRICOSENE TO CONTROL DROSOPHILA SUZUKII

Globachem NV, Sint-Truid...

1. A method for controlling Drosophila suzukii, the method comprising:applying a formulation comprising 9-tricosene on a crop or part of a crop affected by Drosophila suzukii.
US Pat. No. 10,988,629

CORE-SHELL PARTICLE-BASED SECURITY PIGMENT AND METHOD FOR PRODUCTION THEREOF

1. A security pigment, comprising core-shell particles having a core based on an organic addition polymer, a shell based on an organic condensation polymer and a feature substance present in the core in finely dispersed or dissolved form, wherein the addition polymer is a three-dimensionally cross-linked duromer.
US Pat. No. 10,988,630

COATING COMPOSITIONS FOR BUILDING MATERIALS AND COATED BUILDING MATERIAL SUBSTRATES

CERTAINTEED CORPORATION, ...

1. A coating composition adapted to selectively retard water vapor as a function of humidity when cured into a barrier layer, the composition comprising an aqueous dispersion of:a. a hydrophobic component, wherein the hydrophobic component comprises or is derived from a latex of styrene butadiene, vinyl acetate ethylene, wax, polyvinyl chloride, polyvinyl butyral, butadiene, or combinations thereof and wherein the hydrophobic component further comprises or is derived from a latex of styrene acrylic, acrylic, vinylidene chloride, polyethylene, polypropylene, or combinations thereof; and
b. a hydrophilic component present in an amount of at least about 5 wt. % based on a total weight of the hydrophobic and hydrophilic components in a solid coating, wherein the hydrophilic component comprises polyvinyl alcohol (PVOH), poly(vinyl pyrolidone), a salt of polyacrylic acid, poly acrylic acid, a highly carboxylated latex, an amine, an inorganic hydrophilic filler, polyethylene oxide, a vinyl ether, a highly hydrolyzed polymer, or combinations thereof;
c. wherein the composition once cured is effective to provide a variable water vapor perm rating of about 1 perm or less at 25% average RH and about 15 perms or more at 95% average relative humidity, as tested by ASTM E96 at 21° C. and as tested by coating and curing the composition on a kraft paper.
US Pat. No. 10,988,632

COATING COMPOSITION

PPG Industries Ohio, Inc....

1. A coating composition comprisinga) a polyester blend comprising
a first polyester material having a Tg of from 55 to 105° C., the first polyester material being present in the polyester blend in an amount of 60 to 90 wt % based on solids;
a second polyester material having a Tg of from ?10 to 25° C., the second polyester material being present in the polyester blend in an amount of 10 to 40 wt % based on solids; and
b) a crosslinking system comprising
i) an amine crosslinking material;
ii) a phenolic crosslinking material; and
iii) an isocyanate crosslinking material.
US Pat. No. 10,991,449

PREDICTING SUICIDALITY USING A COMBINED GENOMIC AND CLINICAL RISK ASSESSMENT

Indiana University Resear...

1. A method for assessing and mitigating suicidality in a male subject in need thereof, comprising:determining an expression level of at least a first panel of blood biomarkers or a second panel of blood biomarkers in a sample from the subject, where the first panel of blood biomarkers comprises solute carrier family 4 (sodium bicarbonate cotransporter), member 4 (SLC4A4), cell adhesion molecule 1 CADM1, dystrobrevin, alpha (DTNA), spermidine/spermine N1-acetyl transferase 1 (SAT1), interleukin 6 (interferon, beta 2) (IL6), RAS-like family 11 member B (RASL11B), Glutamate Receptor, Ionotropic, Kainate 2 (GRIK2), histone cluster 1, H2bo (HIST1H2BO), jun proto-oncogene (JUN), and GRB2-Associated Binding Protein 1 (GAB1), and where the second panel of blood biomarkers comprises spindle and kinetochore associated complex subunit 2 (SKA2), CAP-GLY domain containing linker protein family, member 4 (CLIP4), kinesin family member 2C (KIF2C), kelch domain containing 3 (KLHDC3), chemokine (C-C motif) ligand 28 (CCL28), v-ets avian erythroblastosis virus E26 oncogene homolog (ERG), adenylate kinase 2 (AK2), Myelin Basic Protein (MBP), and fatty acid desaturase 1 (FADS1);
identifying a male subject having suicidality where the expression level of the blood biomarkers in the first panel is increased relative to a reference expression level, or, the expression level of the blood biomarkers in the second panel is decreased relative to a reference expression level; and,
administering to the male subject identified as having suicidality a drug to treat the suicidality.
US Pat. No. 10,991,961

FUEL CELL SYSTEM AND OXIDE LAYER REMOVAL METHOD

TOYOTA JIDOSHA KABUSHIKI ...

1. A fuel cell system, comprising:a fuel cell including a catalyst;
an oxidant gas supply unit that supplies oxidant gas to the fuel cell;
a flow control unit configured to control a flow rate of the oxidant gas supplied to the fuel cell;
a removal treatment execution unit configured to execute an oxide layer removal treatment that removes an oxide layer generated on the catalyst when operation of the fuel cell shifts from an intermittent operation to a normal operation; wherein the oxide layer removal treatment increases a current in the fuel cell above a current required based on an output request to the fuel cell to reduce a voltage of the fuel cell,
a first determination unit configured to determine whether or not a first condition, indicating a state where an amount of the oxide layer generated on the catalyst is equal to or more than a predetermined first amount, is satisfied, wherein the removal treatment execution unit is configured to execute the oxide layer removal treatment, when the first condition is determined to be satisfied and the operation of the fuel cell system shifts from the intermittent operation to the normal operation;
a current measurement unit that measures the current of the fuel cell; and
a second determination unit configured to determine whether or not a second condition, indicating a state where the amount of the oxide layer generated on the catalyst is equal to or more than a predetermined second amount that is larger than the first amount, is satisfied, wherein the removal treatment execution unit is configured to execute the oxide layer removal treatment, when the normal operation is in execution, the second condition is determined to be satisfied, and the measured current is equal to or less than a predetermined current threshold;
wherein during the intermittent operation a current value of the fuel cell is zero and the flow rate is controlled to maintain the voltage of the fuel cell within a first voltage range that is lower than an open circuit voltage;
wherein during the normal operation a current value is larger than zero and the flow rate is controlled in response to the output request to the fuel cell;
wherein the removal treatment execution unit is configured execute the oxide layer removal treatment by increasing a current in the fuel cell to lower a voltage of the fuel cell to be within a predetermined second voltage range that is lower than the predetermined first voltage range.
US Pat. No. 10,991,450

MATERIALS AND METHODS FOR DETERMINING METABOLIZER STATUS IN HUMANS

Ohio State Innovation Fou...

1. A method of administering a dose of a medication to a human in need thereof, comprising: determining the human's metabolizer status genotype for a panel of cytochrome P450 CYP3A alleles according to the following:i.) extensive metabolizer status if CYP3A4 genotype at rs35599367 is CC and CYP3A5 genotype at rs776746 is AA and CYP3A5 genotype at rs41303343 is a T insertion;
ii.) intermediate metabolizer status if CYP3A4 genotype at rs35599367 is CT and CYP3A5 genotype at rs776746 is AG and CYP3A5 genotype at rs41303343 is a T deletion;
ii.) poor metabolizer status if CYP3A4 genotype at rs35599367 is TT and CYP3A5 genotype at rs776746 is GG and CYP3A5 genotype at rs41303343 is (del T)(del T); administering a dose of medication according to metabolizer status, wherein:
if the human is determined to be an extensive metabolizer, the dose is high,
if the human is determined to be an intermediate metabolizer, the dose is standard, or if the human is determined to be a poor metabolizer, the dose is low;wherein a high dose is 1.5 to 2.5 times a standard dose, and wherein a low dose is 0.25 to 0.75 of a standard dose.
US Pat. No. 10,986,841

BLEACH COMPOSITIONS

The Clorox Company, Oakl...

1. A sanitizing or disinfecting composition comprising:(a) about 0.05% to 0.5% by weight of a hypochlorite or free available halide as provided by an oxidant;
(b) at least one nonionic or zwitterionic surfactant;
(c) a cationic surfactant; and
(d) at least 90% water;
(e) wherein the composition has an R value that is greater than 0, where R is defined as the sum of the concentration of any nonionic or zwitterionic surfactants plus any cationic surfactants, divided by total surfactant concentration;
(e) wherein the composition has a pH from 8 to 12.5;
(f) wherein the sanitizing or disinfecting composition exhibits at least a 3-log reduction in at least one of an M bovis or C. diff population within 10 minutes.
US Pat. No. 10,986,842

MICROBIAL PESTICIDAL COMPOSITION AND PRODUCTION THEREOF

1. A process for harvesting a biomass comprising bacterial cells and/or spores and exhibiting fungicidal activity, comprising:(a) propagating a lipoprotein-producing and/or glycolipid-producing bacterial strain in a growth medium to obtain a culture medium;
(b) ensuring the pH of the culture medium is in a range from 2.5 to 5.5;
(c) optionally, before, during, or after step (b), adding a geopolymer to the culture medium;
(d) separating the biomass from the culture medium having a pH in a range from 2.5 to 5.5;
(e) optionally, adding an excipient to the biomass, and, optionally, adjusting the pH of the biomass to be in a range from 5.5 to 8.0; and
(f) optionally, drying the biomass.
US Pat. No. 10,987,355

METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS

Aneira Pharma, Inc., San...

1. A composition for use in the treatment of hair loss wherein the active agents consist of about 0.05%-0.5% w/v of one selected from the group consisting of latanoprost and latanoprost acid and 1%-8% w/v minoxidil.
US Pat. No. 10,987,356

DUAL INHIBITION OF CDK AND HSP90 DESTABILIZE H1F1 ? AND SYNERGISTICALLY INDUCES CANCER CELL DEATH

Institute For Cancer Rese...

1. A method of treating lung cancer, breast cancer, colon cancer, renal cancer, glioblastoma, or colorectal cancer in a subject in need thereof, comprising:administering a CDK inhibitor to the subject; and
administering an HSP90 inhibitor to the subject;
provided that both RO-3306 and geldanamycin are not administered to the subject.
US Pat. No. 10,991,453

ALIGNMENT OF NUCLEIC ACID SEQUENCES CONTAINING HOMOPOLYMERS BASED ON SIGNAL VALUES MEASURED FOR NUCLEOTIDE INCORPORATIONS

Life Technologies Corpora...

1. A method of aligning nucleic acid sequence information, the method comprising:receiving, at a processor, a plurality of signal values measured in response to one or more nucleotide incorporation events by at least one sample nucleic acid template, the signal values measured by a sensor array in response to a series of nucleotide flows into a plurality of defined spaces coupled to the sensor array, wherein the defined spaces contain the at least one sample nucleic acid template, wherein the series of nucleotide flows has a nucleotide flow order;
calculating a matrix of score values using a local sequence alignment method, the matrix corresponding to a kth nucleobase of the nucleotide flow order to form a plurality of matrices corresponding to the series of nucleotide flows, wherein each matrix includes score values for a plurality of nucleobases of a reference nucleic acid sequence and a plurality of homopolymer lengths from 0 to n, wherein the homopolymer length corresponds to a number of homopolymeric incorporations of the nucleobases associated with a respective nucleotide flow, wherein each score value indicates a degree of fit for the kth nucleobase of the nucleotide flow order with an ith nucleobase of the reference nucleic acid sequence and a jth homopolymer length;
adding weight factors to the score values to form weighted values for each matrix, wherein the weight factors are based upon the respective signal value measured for the kth nucleobase of the nucleotide flow order;
determining respective maximum weighted values in the matrices corresponding to nucleobases of the nucleotide flow order, wherein a maximum weighted value indicates a presence of a respective nucleobase of the reference nucleic acid sequence and a respective homopolymer length for the respective nucleobase of the nucleotide flow order; and
selecting aligned nucleobases and aligned homopolymer lengths based on the respective maximum weighted values to determine an aligned nucleic acid sequence.
US Pat. No. 10,991,967

PREPARATION OF A NEW TYPE OF COMPOSITE ANODE AND MICROBIAL FUEL CELL BASED ON NITROGEN DOPED BIOLOGICAL CARBON AND POROUS VOLCANIC ROCKS

DALIAN UNIVERSITY OF TECH...

1. A preparation method of a composite anode doped nitrogen based on biological carbon and porous volcanic rocks, comprising:(1) preparing dry power sludge by drying activated sludge and calcining the activated sludge at 600˜700° C. without oxygen;
(2) making porous carbon powder doped with nitrogen by purifying the dry powder sludge by acidification;
(3) drying the porous carbon powder doped nitrogen;
(4) selecting volcanic rock particles with more than 40% porosity for purge and deionized water cleaning;
(5) using PVDF as binder, mixing PVDF and drying the porous carbon powder doped with nitrogen in DMF, and then adding the volcano rock particles, evenly coating the porous carbon powder doped with nitrogen on outer surface of the volcano rock particles after mixing; then calcining them at 600-700° C. without oxygen, inoculating new porous carbon particles doped with nitrogen with Shewanella, which is a composite anode doped with nitrogen based on biochar and porous volcano rocks.
US Pat. No. 10,988,384

GRAPHITE-SHEET PROCESSED ARTICLE AND GRAPHITE SHEET PROCESSED ARTICLE MANUFACTURING METHOD

KANEKA CORPORATION, Osak...

1. A method for producing a graphite sheet processed product, comprising:obtaining a graphite sheet by a two-heating step (i) maintaining a polymer film at a temperature of not lower than 2400° C. but below 2800° C. under an inert gas atmosphere for not less than 3 hours and then (ii) graphitizing the polymer film at a maximum temperature of not lower than 2900° C.,
wherein the graphite sheet is subjected to a cut process carried out using at least one of scissors, a cutter, a trimming cutter, a waterjet cutter, a laser cutter, an ultrasonic cutter, or a combined cutter in which the waterjet cutter and the laser cutter are combined.
US Pat. No. 10,988,640

TWO-COMPONENT ADHESIVE COMPOSITION

LG Chem, Ltd.

1. A two-component adhesive composition comprising:(i) a first part including a (meth)acrylate-based monomer mixture including components (a1) to (a3) below:
(a1) an alkyl (meth)acrylate compound, and any one or more of
(a121) a (meth)acrylate compound having an alkoxysilyl group, and
(a122) a (meth)acrylate compound having an unsaturated functional group except for an acryloyl group,
(a2) 50 to 100 parts by weight of an adhesive reinforcing agent relative to the 100 parts by weight of the (meth)acrylate-based monomer mixture, and
(a3) 1 to 10 parts by weight of a filler relative to the 100 parts by weight of the (meth)acrylate-based monomer mixture;
(ii) a second part including components (b1) and (b2) below:
(b1) 100 parts by weight of an epoxy resin, and
(b2) 50 to 150 parts by weight of an initiator with respect to (b1),
wherein (i) the first part and (ii) the second part are mixed in a weight ratio of 1:1 to 20:1.
US Pat. No. 10,986,848

METHODS AND COMPOSITIONS FOR CONSUMABLES

Impossible Foods Inc., R...

1. A ricotta cheese replica comprising:(a) a solidified nut milk comprising 15% or less of insoluble solids from a starting nut milk,
(b) a transglutaminase enzyme,
(c) Lactococcus lactis lactis, and
(d) Lactococcus lactis cremoris, wherein the transglutaminase enzyme was added to the nut milk at an amount between 0.001% and 0.05% weight/volume, and wherein the Lactococcus lactis lactis and Lactococcus lactis cremoris were added to said nut milk comprising 15% or less of insoluble solids milk at 0.02 g/L.
US Pat. No. 10,987,361

TREATING AUTO-IMMUNE AND AUTO-INFLAMMATORY DISEASES

Shenzhen Evergreen Therap...

1. A method for treating a disease selected from chronic obstructive pulmonary disease, oliterative bronchitis, or asthma with symptoms of reduced airflow to lungs due to smooth muscle hypercontractility and airway remodeling of a patient, said method comprising administering to said patient by inhalation a pharmaceutical composition comprising a first treatment agent comprising 17alpha-hydroxyprogesterone caproate (“17-OHPC”) in an amount of from 0.03 mg/L to 0.3 mg/L, a second treatment agent comprising budesonide (“BUD”) at 0.2 g/L, and a pharmaceutically acceptable carrier, wherein the disease is mediated by interleukin-17 (“IL-17”) and an IL-17 level is reduced in said patient after administration of the pharmaceutical composition compared to an IL-17 level in a patient having the disease and without administration of the pharmaceutical composition.
US Pat. No. 10,988,898

METHOD FOR PREPARING ACTIVE CARBON-BASED SPECIAL SYNTHETIC PAPER

HUNAN UNIVERSITY OF SCIEN...

1. A method for preparing active carbon-based special synthetic paper capable of degrading harmful substances in environment, comprising the following steps:(1) stirring 15 to 20 parts by weight of polyurethane particles and 50 to 150 parts by weight of a solvent in a reactor for 30 min, and standing for 48 h to completely dissolve the polyurethane particles in the solvent to obtain a polyurethane solution;
(2) adding 2 to 25 parts by weight of active carbon having harmful substances adsorption property in the polyurethane solution obtained in the step (1), stirring for 1 h, and mixing uniformly to obtain a solid-liquid mixture;
(3) coating the solid-liquid mixture obtained in the step (2) onto a piece of release paper, soaking the release paper coated with the solid-liquid mixture into an aqueous solution of silver nitrate having photocatalytic degradation property, completely curing the solid-liquid mixture to form a film, and soaking the release paper and the film into an aqueous solution of sodium chloride for 30 min;
(4) drying the release paper and the film obtained in the step (3) in an electric blast drying oven for 1 h, and stripping the film from the release paper;
(5) cutting the film product to a proper size as required to obtain the active carbon-based special synthetic paper.
US Pat. No. 10,989,666

OXYGEN DETECTING AGENT COMPOSITION, AND MOLDED ARTICLE, SHEET, PACKAGING MATERIAL FOR OXYGEN SCAVENGER, AND OXYGEN SCAVENGER USING THE SAME

MITSUBISHI GAS CHEMICAL C...

1. An oxygen detecting agent composition comprising a redox dye, a reducing agent and a basic substance,wherein the redox dye is an iron blue pigment and the reducing agent is lactose, and
wherein a mass content of the reducing agent in the oxygen detecting agent composition is from 3 to 50 times higher than a mass content of the iron blue pigment.
US Pat. No. 10,986,851

CONTROL OF PATHOGENIC BACTERIA IN FOODS

NEVADA NATURALS INC., Al...

1. A preservative composition comprising:a lecithin having a HLB between 7 and 12 and being present in an amount of about 0.05 to about 30.0 percent by weight of the composition; and
a N?—(C8-C18) acyl arginine alkyl (C1-C8) ester salt;
a glycerol monoester of a fatty acid present in an amount of about 0.01 to about 7.5 percent by weight of the composition; or a sugar monoester of a fatty acid present in an amount of about 0.02 to about 15.0 percent by weight of the composition; and
optionally, a chelating agent.
US Pat. No. 10,987,364

SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

LABORATORIOS LEON FARMA S...

1. A pharmaceutical composition comprising:6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone in the form of particles that have: (i) a median particle size ranging from 15 micrometers (?m) to 25 ?m, (ii) a d90 particle size of less than 100 ?m; and (iii) a d10 particle size of more than 3 ?m, wherein the 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone is present in an amount ranging from 3 milligrams (mg) to 4.5 mg; and
one or more pharmaceutically acceptable excipients,
wherein the pharmaceutical composition does not comprise estrogen; and
wherein the pharmaceutical composition is formulated such that no more than 50% of the 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone initially present in the pharmaceutical composition is dissolved within 30 minutes if subjected to an in vitro dissolution test according to the USP XXIII Paddle Method.
US Pat. No. 10,988,645

NON-FLAMMABLE CONTACT ADHESIVE

WILSONART LLC, Austin, T...

1. A non-flammable contact adhesive, comprising:a chemically distinct solvent comprised of a mixture of flammable and non-flammable components;
chemically distinct copolymer rubbers;
chemically distinct tackifiers;
chemically distinct stabilizer resins; and
carbon dioxide gas.
US Pat. No. 10,988,390

GAS/LIQUID PLASMA REACTOR WITH PULSED POWER SUPPLY AND SECONDARY DIRECT CURRENT ELECTRODES

FLORIDA STATE UNIVERSITY ...

1. A reactor system for reacting liquid phase chemical species in a liquid, comprising:a reactor vessel for containing the liquid phase and a gas phase, and having a liquid-gas interface location within the reactor vessel;
a pulsed discharge cathode and anode for creating a pulsed discharge electric field at the liquid-gas interface location;
a pulsed discharge power supply for delivering a pulsed power input to the pulsed discharge cathode and anode, and thereby creating a plasma comprising ions at the liquid-gas interface location;
a secondary electric field source for directing a secondary electric field transverse to the liquid-gas interface;
wherein the secondary electric field will drive some of the ions from the gas phase into the liquid phase to react with the liquid phase chemical species.
US Pat. No. 10,987,366

METHODS AND COMPOSITIONS FOR PROTECTION OF CELLS AND TISSUES FROM COMPUTED TOMOGRAPHY RADIATION

The University of Chicago...

1. A method of inhibiting genomic instability in a subject caused by computed tomography (CT) scan radiation comprising administering to the subject an effective dose of a phosphorothioate compound or derivative thereof prior to and/or following exposure to the CT scan radiation wherein the phosphorothioate compound or derivative thereof is selected from amifostine, WR-1065, WR-638, WR-3689, WR-2822, WR-2529, WR-77913, WR-255591, WR-2823, WR-33278, WR-255709, WR-151326, and WR-151327; wherein:the radiation dose is 1-25 cGy; and
inhibiting genomic instability is selected from reducing micronuclei formation, reducing ?-H2AX formation, reducing chromosome translocation frequency, reducing HPRT mutant frequency, and reducing hyper-recombination.
US Pat. No. 10,988,650

NON-FLAMMABLE MIXED REFRIGERANT CAPABLE OF REDUCING GREENHOUSE EFFECT AND USE THEREOF

JIANGXI TIANYU CHEMICAL C...

1. A mixed refrigerant comprising, by mass fraction, 30% of R134a, 49% of R1234ze(E), and 21% of R1234yf; or22% of R134a, 48% of R1234ze(E), and 30% of R1234yf; or
11.3% of R134a, 69.8% of R1234ze(E), and 18.9% of R1234yf; or
10.1% of R134a, 54.5% of R1234ze(E), and 35.4% of R1234yf; or
10% of R134a, 34% of R1234ze(E), and 56% of R1234yf.
US Pat. No. 10,986,857

DIETARY SUPPLEMENTATION WITH MIXED ALKALI SALTS

LithoLyte Corporation, M...

1. A composition consisting of:sodium bicarbonate;
potassium citrate;
magnesium citrate; and
a sugar alcohol.
US Pat. No. 10,987,627

REDUCING THE EMISSION OF NITROGEN OXIDE WHEN STARTING UP SYSTEMS FOR PRODUCING NITRIC ACID

thyssenkrupp Industrial S...

1. A method, comprising:generating nitrogen oxides (NOx) in a nitric acid production plant;
directing the NOx into an absorption tower of the nitric acid production plant and removing tail gas comprising unabsorbed NOx from the absorption tower; and
reducing the concentration of NOx, in the tail gas obtained during startup of the nitric acid production plant,
wherein the tail gas is heated from a starting temperature, through a threshold temperature, and to an operating temperature at which steady-state operation of the nitric acid production plant for preparation of nitric acid can be effected,
passing the tail gas through a storage medium for NOx and storing at least a portion of the NOx in the storage medium while the temperature of the tail gas is below the threshold temperature, wherein a selective catalytic reduction (SCR) catalyst serves as the storage medium;
combining, when the temperature of the tail gas exceeds the threshold temperature, the NOx in the storage medium with a reducing agent for NOx in the presence of the SCR catalyst, which results in catalytic reduction of at least a portion of the NOx in the storage medium;
measuring, when the temperature is below the operating temperature, a concentration of the NOx in the tail gas before the tail gas contacts the SCR catalyst; and
metering, based on said measuring of the concentration of the NOx, an amount of the reducing agent sufficient to degrade the NOx already adsorbed on the SCR catalyst and the measured concentration of the NOx.
US Pat. No. 10,987,373

DNA ORIGAMI NANOSTRUCTURES FOR TREATMENT OF ACUTE KIDNEY INJURY

ARIZONA BOARD OF REGENTS ...

1. A method of treating acute kidney injury (AKI), the method comprising administering an effective amount of a DNA origami nanostructure to a subject afflicted with AKI to increase an excretory function of said subject.
US Pat. No. 10,988,656

RESIN COMPOSITION

LG Chem, Ltd.

1. A resin composition, comprising:a resin component; and
600 parts by weight or more of a thermally conductive filler relative to 100 parts by weight of the resin component,
wherein the thermally conductive filler comprise 35 to 45 wt % of a first thermally conductive filler having a D50 particle diameter (A) of 35 ?m or more, 25 to 45 wt % of a second thermally conductive filler having a D50 particle diameter (B) in a range of 15 ?m to 30 ?m, and 15 to 35 wt % of a third thermally conductive filler having a D50 particle diameter (C) of 1 to 4 ?m, based on the total weight of the thermally conductive filler,
wherein the resin composition has a thermal conductivity of 3.0 to 50.0 W/mK.
US Pat. No. 10,987,378

UNIVERSAL CARDIOPLEGIC SOLUTION (VARIANTS)

1. A method of providing blood cardioplegic heart protection at a temperature of 25-37° C. using a cardioplegic solution, the method comprising:providing the cardioplegic solution comprising:
potassium chloride: 3-15 g;
magnesium sulfate: 0-2.93 g;
diuretic providing osmolarity within 275-460 mOsmol/kg;
acid and base to attain the solution's pH within 7.1-8.9;
distilled water: up to 1000 ml;
administering via a single injection the cardioplegic solution to a patient in need thereof in a mixture with the patient's autoblood in a ratio from 1:1 to 1:10,
maintaining the patient, the patient's autoblood, and the mixture at a temperature of 25-37° C. using a heart-lung machine,
wherein before, during, or after the single injection, no further injections of the cardioplegic solution or another cardioplegic solution are applied.
US Pat. No. 10,991,987

SOLID STATE BATTERIES

TOYOTA MOTOR EUROPE, Bru...

1. A solid state battery comprising a stack of cells, each cell comprising a positive electrode, a negative electrode and a solid electrolyte disposed between the positive electrode and the negative electrode, wherein a current collector is disposed between the negative electrode of a first cell and the positive electrode of a second cell, the second cell being adjacent to the first cell, the solid state battery comprising an ionic conductor being configured to move into two positions, the two positions comprising a normal position wherein the ionic conductor is not in contact with the current collector and a short-circuit position wherein the ionic conductor is in contact with the current collector, the negative electrode of the first cell and the positive electrode of the second cell and wherein the ionic conductor has an ionic conductivity which smaller than an electronic conductivity of the current collector.
US Pat. No. 10,988,405

INTERMEDIATE TO HIGH CTE GLASSES AND GLASS ARTICLES COMPRISING THE SAME

Corning Incorporated, Co...

1. A glass composition comprising:63 mol % to 73 mol % SiO2,
5 mol % to 11 mol % Al2O3,
4 mol % to 8 mol % B2O3,
0 mol % to 1 mol % Na2O,
5 mol % to 13 mol % K2O,
0 mol % to 4 mol % MgO,
2 mol % to 9 mol % CaO,
2 mol % to 7 mol % SrO,
0 mol % to 5 mol % BaO, and
4 mol % to 16 mol % R?O,
wherein R?O comprises the sum of the mol % of MgO, CaO, SrO, and BaO in the composition.
US Pat. No. 10,988,407

MANUFACTURING PROCESS FOR STRIAE-FREE MULTICOMPONENT CHALCOGENIDE GLASSES VIA MULTIPLE FINING STEPS

The Government of the Uni...

1. A striae-free chalcogenide glass made by the method, comprising:loading germanium, arsenic, sulfur, and selenium precursors into an ampoule, wherein the germanium, arsenic, sulfur, and selenium precursors are sufficient to constitute a glass with the composition of x % at. germanium, y % at. arsenic, z % at. selenium, and (100-x-y-z) % at. sulfur, wherein 0.5?x?10, 30?x+y?45, and 0.5?z?10, sealing the ampoule, and placing the ampoule in a rocking furnace, wherein the rocking furnace comprises a top zone and a bottom zone, wherein the top and bottom zones are two independently controllable temperature zones;
heating both the top and bottom zones at a rate of 3° C. per minute to a Step 1 temperature, wherein the Step 1 temperature is the same for both the top and bottom zones;
maintaining the Step 1 temperature in the top and bottom zones while rocking the furnace at an inclination angle of +45° for 15 hours;
increasing the temperature of the top zone at a rate of 0.6° C. per minute to a Step 3 top zone temperature and decreasing the temperature of the bottom zone at a rate of 0.6° C. per minute to a Step 3 bottom zone temperature while rocking the furnace at an inclination angle of +45°, wherein there is a temperature gradient of 100° C. between the Step 3 top zone temperature and the Step 3 bottom zone temperature;
setting the furnace to a vertical position and maintaining the Step 3 top zone temperature and the Step 3 bottom zone temperature for 3 hours;
decreasing the temperature of the top zone at a rate of 10° C. per minute to a Step 5 top zone temperature, decreasing the temperature of the bottom zone at a rate of 10° C. per minute to a Step 5 bottom zone temperature, and maintaining the Step 5 top zone temperature and Step 5 bottom zone temperature for 3 hours, wherein the Step 5 top zone temperature is 100° C. lower than the Step 3 top zone temperature, and wherein the Step 5 bottom zone temperature is 100° C. lower than the Step 3 bottom zone temperature;
decreasing the temperature of the top zone at a rate of 10° C. per minute to a Step 6 top zone temperature, decreasing the temperature of the bottom zone at a rate of 10° C. per minute to a Step 6 bottom zone temperature, and maintaining the Step 6 top zone temperature and Step 6 bottom zone temperature for 3 hours, wherein the Step 6 top zone temperature is 100° C. lower than the Step 5 top zone temperature, and wherein the Step 6 bottom zone temperature is 100° C. lower than the Step 5 bottom zone temperature;
decreasing the temperature of the top zone at a rate of 10° C. per minute to a Step 7 top zone temperature, decreasing the temperature of the bottom zone at a rate of 10° C. per minute to a Step 7 bottom zone temperature, and maintaining the Step 7 top zone temperature and Step 7 bottom zone temperature for 30 minutes, wherein the Step 7 top zone temperature is at least 100° C. lower than the Step 6 top zone temperature, and wherein the Step 7 bottom zone temperature is at least 100° C. lower than the Step 6 bottom zone temperature; and
removing the ampoule from the furnace and water quenching the glass.
US Pat. No. 10,987,383

BIOPOLYMER COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GASTRIC ULCERS

Promend Animal Health, In...

1. A composition for the treatment of a gastric ulcer, the composition comprising manuka honey and a biopolymer selected from the group consisting of chitosan, cellulose, and alginate in a form suitable for oral administration.
US Pat. No. 10,987,385

COMPOSITIONS FOR FECAL FLORAL TRANSPLANTATION AND METHODS FOR MAKING AND USING THEM AND DEVICES FOR DELIVERING THEM

Finch Therapeutics Holdin...

1. A method of treating seizures in a patient in need thereof, the method comprising:administering to said patient a pharmaceutical preparation comprising a substantially entire microbiota of a stool and a cryoprotectant.
US Pat. No. 10,987,386

METHOD FOR TREATING INFLAMMATION OR CANCER USING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEI

MD HEALTHCARE INC., Seou...

1. A method of alleviating or treating an inflammation disease or a cancer, the method comprising administering to a subject in need thereof a composition comprising an effective amount of an extracellular vesicle derived from Lactobacillus paracasei, wherein the extracellular vesicles are isolated from a culturing solution comprising Lactobacillus paracasei bacterial cells.
US Pat. No. 10,987,387

COMPOSITIONS COMPRISING BACTERIAL STRAIN

4D Pharma Research Limite...

1. A pharmaceutical composition that comprises:a lyophilized Enterococcus gallinarum bacteria strain deposited under NCIMB 42761; and
a pharmaceutically acceptable excipient, diluent, or carrier.
US Pat. No. 10,987,389

ANTI-TUMOR TRADITIONAL CHINESE MEDICINE MICROBIAL FERMENTATION PREPARATION AND A PREPARATION METHOD AND APPLICATION THEREOF

1. An anti-tumor Chinese medicine microbial fermentation preparation, comprising a mixture of raw Chinese medicines and a fermentation extract, wherein the raw medicines comprise the following components in part by weight: 15 to 40 parts of Dioscorea bulbifera, 2 to 30 parts of pangolin scales, 5 to 35 parts of Rheum officinale, 2 to 30 parts of Concha ostreae, 5 to 40 parts of Bombyx batryticatus, 5 to 25 parts of kelp, 5 to 30 parts of Prunella vulgaris, 2 to 20 parts of Ligusticum wallichii, 2 to 30 parts of Sculellaria barbata, 2 to 30 parts of Flos lonicerae, 8 to 40 parts of Oldenlandia diffusa, 2 to 30 parts of Radix trichosanthis, 2 to 40 parts of Rhizoma anemarrhenae, 2 to 35 parts of Radix scutellariae, 2 to 35 parts of Radix angelicae sinensis, 8 to 30 parts of Fructus psoraleae, 2 to 30 parts of Lucid ganoderma, and 2 to 30 parts of Semen coicis; wherein there are 15 to 40 parts by weight of the fermentation extract; and the fermentation extract is Pleurotus sp.
US Pat. No. 10,987,391

METHOD OF AGGLOMERATING CANNABIS EXTRACT WITH ENERGIZING CONSUMABLES

1. A method of combining energizing consumables with Cannabis extract, the method comprising:producing consumable foodstuffs which contain an energizing active ingredient;
producing Cannabis extract containing cannabinoids;
and
agglomerating the consumable foodstuffs and the Cannabis extract into edible material selected from baked goods, a food bars, or candy,
wherein the material contains at least 5.1 mg of tetrahydrocannabinol per serving;
and
wherein the material contains at least 101 mg of caffeine per serving.
US Pat. No. 10,987,648

FUNCTIONALIZED SURFACES AND PREPARATION THEREOF

Twist Bioscience Corporat...

1. A method for surface patterning, the method comprising:applying a first set of molecules to a surface of a structure, wherein each of the first set of molecules binds to the surface and comprises a reactive group capable of binding to a nucleoside;
synthesizing a first layer of oligonucleotides, wherein each oligonucleotide in the first layer of oligonucleotides comprises about 10 to about 100 bases in length and extends from the surface;
applying electromagnetic radiation (EMR) to a predetermined region of the surface to selectively remove a portion of the layer of oligonucleotides, wherein the EMR comprises a wavelength from about 100 nm to about 300 nm; and
synthesizing a second layer of oligonucleotides, wherein each oligonucleotide in the second layer of oligonucleotides extends oligonucleotides from the remaining portion of the first layer of layer of oligonucleotides.
US Pat. No. 10,992,003

AIR-BREATHING AQUEOUS SULFUR RECHARGEABLE BATTERIES

Massachusetts Institute o...

1. An electrochemical apparatus comprising:a catholyte comprising at least one metal salt dissolved in water, thereby providing at least one metal ion;
an anolyte comprising a polysulfide solution; and
a separator, disposed between the anolyte and the catholyte, permeable to the at least one metal ion,
wherein the catholyte, the anolyte, and/or the separator are configured such that:
during a charging process of the electrochemical apparatus, oxygen is generated in the catholyte, the polysulfide in the polysulfide solution undergoes a reduction reaction in the anolyte, and the at least one metal ion moves from the catholyte to the anolyte, and
during a discharging process of the apparatus, the oxygen is consumed in the catholyte, the polysulfide oxidizes in the anolyte, and the at least one metal ion moves from the anolyte to the catholyte.
US Pat. No. 10,987,652

GAS ABSORPTION MATERIAL, USE OF SAME FOR GAS ABSORPTION, GAS ABSORPTION BODY, GAS ABSORPTION METHOD, ACIDIC GAS ABSORPTION DEVICE, ACIDIC GAS RECOVERY DEVICE, WATER VAPOR ABSORPTION DEVICE, WATER VAPOR RECOVERY DEVICE, HEAT EXCHANGER, AND HEAT RECOVERY DE

KYUSHU UNIVERSITY, NATION...

1. A gas absorption material, comprising particles of a polymer compound containing amino groups and an amine-containing compound having a molecular weight of 61 to 10000, wherein the polymer compound containing amino groups reversibly absorbs and desorbs an acid gas.
US Pat. No. 10,988,422

HYDROFLUOROALKANE COMPOSITION

THE CHEMOURS COMPANY FC, ...

1. A liquid phase composition comprising:a catalyst comprising SbF5 and a hydrofluoroalkane composition comprising at least one hydrofluoroalkane selected from the group consisting of RCH2CHFCl, RCH2CFCl2, and RCH2CH2F;
wherein R is trifluoromethyl or pentafluoroethyl; and
wherein the hydrofluoroalkane composition comprises greater than 95 mol % of the at least one hydrofluoroalkane.
US Pat. No. 10,991,494

NON-ORIENTED ELECTRICAL STEEL SHEET

NIPPON STEEL CORPORATION,...

1. A non-oriented electrical steel sheet, comprising a chemical composition represented by:in mass %,
C: 0.0030% or less;
Si: 2.00% to 4.00%;
Al: 0.10% to 3.00%;
Mn: 0.10% to 2.00%;
S: 0.0030% or less;
one kind or more selected from a group consisting of Mg, Sr, Ba, Ce, La, Nd, Pr, Zn, and Cd: 0.0015% to 0.0100% in total;
a parameter Q represented by an equation 1 when the Si content (mass %) is set to [Si], the Al content (mass %) is set to [Al], and the Mn content (mass %) is set to [Mn]: 2.00 or more;
Sn: 0.00% to 0.40%;
Cu: 0.0% to 1.0%;
Cr: 0.0% to 10.0%; and
a balance: Fe and impurities, wherein:
the total mass of S contained in sulfides or oxysulfides of Mg, Sr, Ba, Ce, La, Nd, Pr, Zn, or Cd is 40% or more of the total mass of S contained in the non-oriented electrical steel sheet;
a {100} crystal orientation intensity is 3.0 or more;
a thickness is 0.15 ram to 0.30 mm; and
an average crystal grain diameter is 65 ?m to 100 ?m,
Q=[Si]+2[Al]?[Mn]  (Equation 1).
US Pat. No. 10,987,398

HERBAL COMPOUND EXTRACT TO MODERATE DIABETES WITH LIVER NECROSIS AND FIBROSIS AND USE THEREOF

OMICS LIFESCIENCE CO., LT...

1. A herbal composition for moderating diabetes with liver necrosis and fibrosis; wherein the herbal composition comprises in a therapeutically effective amount therefor a mixture of herbals obtained from an ethanolic extract of a mixture of (i) rhizome of Dendrobium nobile Lindl, (ii) fruiting body of Antrodia camphorata, (iii) root of Panax ginseng C. A. Mey, (iv) root of Rehmannia glutinosa Libosch, (v) rhizome of Salvia miltiorrhiza Bge., (vi) all of Pheretima aspergillum (E.Perrier), (vii) root of Pueraria mirifica, (viii) fruit of Schisandra chinensis (Turcz.) Baill. and (ix) rhizome of Glycyrrhiza uralensis Fisch.
US Pat. No. 10,987,910

FOAM AS ADHESIVE FOR COMPOSITES FOR THERMAL INSULATION

BASF SE, Ludwigshafen (D...

1. A process for the preparation of a composite comprising at least layers (L1), (L2) and a binder layer (LB) located between layers (L1) and (L2), the process comprising:(i) applying a foamed composition (C1) comprising an inorganic binder on one surface of the layer (L1) or layer (L2) or layer (L1) and (L2) to form the binder layer (LB),
(ia) layer (L1) comprising from 25 to 95% by weight of aerogel and from 5 to 75% by weight of fibers and from 0 to 70% by weight of fillers, and
(ib) layer (L2) comprising from 25 to 95% by weight of aerogel and from 5 to 75% by weight of fibers and from 0 to 70% by weight of fillers; and
(ii) combining the layer (L1) and the layer (L2) in a manner that the binder layer (LB) comprising the foamed composition (C1) is located between the layer (L1) and the layer (L2);
(iii) pressing to compress the binder layer (LB) between the layer (L1) and the layer (L2); and
(iv) curing and/or drying the foamed composition (C1) in the binder layer (LB) between the layer (L1) and the layer (L2) to form the composite; and
wherein the composite has a tensile strength that is greater than a tensile strength of a comparable laminate that is the same as the composite except made with an unfoamed composition.
US Pat. No. 10,988,423

GAS-PHASE CATALYTIC FLUORINATION WITH CHROMIUM CATALYSTS

Arkema France, Colombes ...

1. Process for the fluorination of a chlorinated C3 alkane or alkene compound having at least one chlorine atom into a fluorinated C3 alkane or alkene compound having at least one fluorine atom comprising the following steps:a. contacting, in a reactor, the chlorinated compound with hydrogen fluoride in gas phase in the presence of a fluorination catalyst to produce a fluorinated compound, and
b. regenerating the fluorination catalyst used in step a),wherein the step (b) of regenerating the fluorination catalyst comprises (c) the treatment of said fluorination catalyst with an oxidizing agent-containing gas flow to form an oxidized fluorination catalyst, and (d) the treatment of the oxidized fluorination catalyst obtained in step (c) with a gaseous mixture comprising a reducing agent and an inert gas; the catalyst regenerated in step b) being reused in step a) and the reducing agent being selected from the group consisting of C1-C10 hydrohalocarbons.
US Pat. No. 10,988,426

CONTINUOUS PROCESSES FOR THE HIGHLY SELECTIVE CONVERSION OF ALDOHEXOSE-YIELDING CARBOHYDRATE TO ETHYLENE GLYCOL

Iowa Com Promotion Board,...

1. A highly selectivity, continuous process for converting aldohexose in an aldohexose-yielding carbohydrate feed to ethylene glycol by retro-aldol conversion of the aldohexose to glycolaldehyde and hydrogenation of glycolaldehyde to ethylene glycol, comprising:a. continuously or intermittently passing said carbohydrate-containing feed into a reaction zone having an aqueous, hydrogenation medium containing homogeneous retro-aldol catalyst, hydrogen and hydrogenation catalyst;
b. providing at least one pH control agent to the hydrogenation zone to maintain the hydrogenation medium at a pH between about 3 and 8;
c. maintaining the aqueous, hydrogenation medium in the reaction zone at hydrogenation conditions to provide a product solution comprising ethylene glycol, said hydrogenation conditions being at retro-aldol conditions of a temperature between about 230° C. and 300° C. and providing a ratio of retro-aldol catalyst to hydrogenation catalyst, and a hydrogen partial pressure that, in combination are sufficient to provide a conversion efficiency of said aldohexose to ethylene glycol of at least 60 percent, wherein said carbohydrate feed is at least partially hydrated and is under a pressure sufficient to maintain partial hydration; wherein said carbohydrate feed is below a temperature of about 170° C.; and wherein said carbohydrate-containing feed is rapidly heated to above 230° C.; and
d. continuously or intermittently withdrawing said product solution from the reaction zone, which withdrawn product contains retro-aldol catalyst.
US Pat. No. 10,989,706

VACUUM-ASSISTED PLASMA SEPARATION

Siemens Healthcare Diagno...

1. An apparatus, comprising:a housing having a first surface;
a blood separation well formed at the first surface of the housing for collection of a blood sample, the blood separation well having a recess intersecting a second surface of the blood separation well;
a separation membrane positioned on the second surface of the recess for filtration of the blood sample to provide filtered plasma;
a plasma collection vessel within the housing, the plasma collection vessel having a proximal end and a distal end, the distal end positioned at the first surface of the housing, the plasma collection vessel including a seal configured to be pierced by a pipette;
a first channel extending within the housing, and connecting the blood separation well to the plasma collection vessel proximate to the second surface of the recess; and,
a second channel connecting the plasma collection vessel to a first outlet port, wherein the plasma collection vessel and the first channel are configured to convey a pressure force to provide filtered plasma to the plasma collection vessel.
US Pat. No. 10,987,658

LOW WASHCOAT LOADING SINGLE LAYER CATALYSTS FOR GASOLINE EXHAUST GAS APPLICATIONS

Johnson Matthey Public Li...

1. A catalyst article for treating exhaust gas comprising:a substrate; and
a single catalyst layer deposited directly on the substrate;
wherein the single catalyst layer comprises a first platinum group metal (PGM) component, an oxygen storage component (OSC) material, and an inorganic oxide;
wherein the single catalyst layer has a total washcoat loading of no greater than 1.4 g/in3;
wherein the OSC material loading in the single catalyst layer is less than 1.2 g/in3; and
wherein the substrate is a flow-through monolith.